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8ABSTRACT
Introduc? on
By understanding the eff ect that anesthesiological interventions, patient positioning, and 
neurosurgical pathologies have on regulatory mechanics of cerebral blood fl ow and oxygen 
consumption, it is possible to guarantee suffi  cient blood fl ow and oxygenation of the brain and 
to provide good surgical conditions for a neurosurgeon. Perioperative fl uid administration 
should have a minimal eff ect on blood coagulation in neurosurgery. Optimal hemoglobin 
level in the neurosurgical patient population is unknown. Transfusion of blood products itself 
may be associated with worse outcome. Good hemodynamic control and well-planned patient 
positioning are important to ensure suffi  cient cerebral perfusion pressure (CPP) and to minimize 
intraoperative bleeding. 
Th e objective of this thesis was to examine clinically important aspects of neuroanesthesia 
regarding cerebral blood fl ow and perfusion pressure, blood coagulation, and transfusion of 
blood products in neurosurgical patients.
Pa? ents and methods
Th is study consists of 130 adult and two pediatric neurosurgical patients and 10 healthy 
volunteers (Studies III-VI). In addition, Studies I and II include a retrospective review of 1014 
plus 488 patients’ (partly the same patients) medical records. 
Data on patients operated on for ruptured cerebral arterial aneurysm at Helsinki University 
Hospital between 2006 and 2009 (Study I) and at Helsinki University Hospital and Turku 
University Hospital between 2003 and 2008 (Study II) were reviewed to calculate the transfusion 
rates of blood products (Study I) and the incidence of adenosine use (Study II). Possible risk 
factors for red blood cell (RBC) transfusion (RBCT) and its eff ect on outcome were also 
investigated. 
Rotational thromboelastometry (Rotem®) analysis was used to evaluate the ability of fresh 
frozen plasma (FFP) and RBCT to maintain adequate coagulation capacity in two pediatric 
neurosurgical patients suff ering from massive bleeding during craniotomy (Study III) and to 
compare the eff ect of equimolar and equivolemic solutions of mannitol and hypertonic saline on 
blood coagulation in vitro (Study IV). 
Eff ect of change in mean arterial pressure (MAP) on the diff erence between arterial carbon 
dioxide partial pressure (PaCO2) and end-tidal concentration of carbon dioxide (EtCO2) was 
measured from patients anesthetized for craniotomy to test reliability of EtCO2 as an estimate of 
PaCO2 (Study V). Aft er data combination from two previously conducted, separate prospective 
trials comparing stroke volume (SV)-directed administration of hydroxyethyl starch (HES 
130/0.4) and Ringer’s acetate (RAC) in prone and sitting positions during neurosurgery, the 
diff erences in SV-directed fl uid administration between the two diff erent positions were 
measured with the purpose of determining whether one of the fl uids would be more benefi cial 
than the other in achieving stable hemodynamics (Study VI).  
9Results
Intraoperative transfusion rates for RBC, FFP, and platelet transfusion intraoperatively were 
7.6%, 3.1%, and 1.2%, respectively. RBCT was associated with intraoperative rupture of an 
aneurysm. Lower preoperative hemoglobin value, worse Fisher grade, and intraoperative rupture 
of an aneurysm independently increased the likelihood of intraoperative RBCT. Intraoperative 
RBCT increases the patient’s risk for worse neurological outcome, even when controlled with 
other variables, such as the World Federation of Neurological Surgeons (WFNS) classifi cation 
and Fisher grade. With early perioperative transfusion of RBC and FFP, it is possible to preserve 
normal coagulation capacity when massive bleeding during surgery is expected.
A total of 16 of 1014 patients operated on for ruptured cerebral arterial aneurysm received 
adenosine during surgery. All but one adenosine administration was related to intraoperative 
rupture of an aneurysm. Th e median single dose for adenosine was 12 (range 6-18) mg and the 
median cumulative dose 27 (18-89) mg. Aft er 10 min of adenosine administration, patients had 
stable hemodynamics and no adverse eff ects were reported. 
A 15% mannitol solution in 10 vol% and 20 vol% dilutions impaired coagulation more than 
an equiosmolar 2.5% saline in vitro. Overall, mannitol disturbed coagulation more than any 
other study solution. An increment in the concentration of saline solution resulted in a weaker 
clot.
Th e percentage change in MAP had a positive correlation with measured PaCO2-EtCO2 
diff erence aft er anesthesia induction in the craniotomy patient population. 
Study fl uid consumption did not diff er between the two surgery positions. Th e cumulative 
dose of RAC (prone and sitting position combined) to optimize fl uid fi lling at 30 min aft er 
surgery was higher than the dose of HES (ratio 1.5:1). Patients in a sitting position had a lower 
MAP over time and higher cardiac and stroke volume indices than patients in a prone position.
Conclusion
Intraoperative RBCT may itself worsen SAH patients’ neurological outcome. In the event of 
sudden intraoperative rupture of an aneurysm, adenosine-induced asystole can be used to stop 
the bleeding and facilitate clipping of the aneurysm. Early infusion of FFP instead of crystalloids 
should be considered to compensate for expected excess bleeding in neurosurgery to preserve 
normal coagulation capacity. Moreover, hypertonic saline might be a more favorable solution 
than mannitol in treating elevated intracranial pressure due to its less harmful eff ect on blood 
coagulation. 
Hemodynamic changes make EtCO2 unreliable in estimating PaCO2. Th erefore, optimal 
ventilation before neurosurgery should be confi rmed by arterial blood gas analysis. Preemptive 
goal-directed fl uid administration with either RAC or HES solutions before positioning enables 
a stable hemodynamic state during neurosurgery in both prone and sitting positions. Fluid 
requirement did not diff er between the two surgery positions, and the ratio of HES:RAC to 
achieve comparable hemodynamics is 1:1.5.
 
10
11
Th e main goal of neuroanesthesia is to 
maintain adequate cerebral perfusion pressure 
(CPP) and, consequently, cerebral blood fl ow 
(CBF) to guarantee suffi  cient oxygenation of 
the brain. Moreover, neuroanesthesia aims 
to provide good surgical conditions for the 
neurosurgeon and to use available tools 
such as drug therapy for neuroprotection in 
situations where there is a risk of decreased 
oxygen delivery to the brain [1]. To succeed 
in these goals, the anesthesiologist must 
have adequate knowledge of the eff ect 
that anesthetics, intravenous fl uids, other 
anesthesiological interventions, and 
neurosurgical pathologies have on CBF, CPP, 
autoregulation, carbon dioxide reactivity, 
brain metabolism, and fl ow-metabolic 
coupling. Autoregulation of CBF is oft en, 
at least partially, disturbed in neurosurgical 
patients [2]. Th erefore, good hemodynamic 
control of the patient during neurosurgery 
is essential to maintain adequate CPP and 
to prevent intraoperative blood loss. As 
intracranial pressure (ICP) monitoring is not 
always feasible in the perioperative phase, 
MAP alone provides a CPP approximation.
No specifi c guidelines exist for fl uid 
therapy in neurosurgical patients. To prevent 
sudden changes in plasma osmolarity, 
hypotonic fl uids should be avoided [3]. 
Normal coagulation capacity is essential in 
neurosurgery, and therefore, perioperative 
fl uid administration should be planned in 
a way that does not jeopardize coagulation 
[4]. Artifi cial colloids are known to have 
a negative eff ect on blood coagulation 
[5-7]. Regarding intraoperative fl uid 
administration, colloids have been thought 
to be superior to crystalloids in increasing 
hypovolemic patients’ intravascular volume 
and cardiac stroke volume, but recent fi ndings 
indicate that the diff erence might be notably 
smaller than earlier believed [8-10]. Recent 
controversies regarding colloid safety have, 
however, diminished their use [11,12]. 
Optimal hemoglobin level in the 
neurosurgical patient population is unknown, 
and transfusion of blood products itself 
may be associated with worse outcome 
[13]. On the other hand, early transfusion 
of blood products might be needed during 
neurosurgery in order to maintain normal 
coagulation capacity. Stable hemodynamics 
and treatment of hypertension in the 
perioperative phase are essential in preventing 
bleeding complications [14,15]. Controlled 
hypotensive anesthesia especially in cerebral 
arterial aneurysm surgery was previously 
used to prevent bleeding and intraoperative 
rupture of an aneurysm, but this practice is 
no longer supported due to complications 
associated with hypotensive anesthesia [16]. 
However, adenosine-induced cardioplegia is a 
relatively novel method to facilitate temporary 
clipping in the event of intraoperative rupture 
of an aneurysm, potentially also decreasing 
the risk of red blood cell transfusion (RBCT) 
[17].  
Osmotherapy plays an important role 
in neuroanesthesia. As water movement 
between an intact blood-brain barrier (BBB) 
is guided by the osmotic gradient between 
plasma and the brain, both mannitol and 
hypertonic saline (HS) can be used to reduce 
ICP by increasing plasma osmolarity [18]. 
Th ey are equally eff ective in reducing ICP and 
also carry a risk of certain clinically important 
side-eff ects [19-21]. Although BBB is 
practically impermeable to HS and mannitol, 
an impaired BBB can cause leakage of both 
sodium and mannitol into the cerebrospinal 
fl uid [22]. Mannitol and HS may interfere 
with blood coagulation, but data comparing 
these two solutions do not exist [6,23,24].
CBF is strongly regulated by arterial CO2 
partial pressure (PaCO2). Hypoventilation 
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causes vasodilation in cerebral arteries and 
increases CBF and potentially ICP, whereas 
hyperventilation causes vasoconstriction 
and a decrease in CBF [2]. An increase in 
PaCO2 may cause a marked increase in ICP 
in situations where other compensatory 
mechanics have already been exhausted. 
Th erefore, it is of the utmost importance to 
prevent hypoventilation in neurosurgical 
patients during anesthesia induction, bearing 
in mind that CO2 reactivity is disturbed in 
hypotension [25,26]. 
Some neurosurgical procedures can 
be performed in either the sitting or prone 
position. Both of these positions in general 
anesthesia expose the patient to hemodynamic 
alternations, i.e. hypotension and changes 
in cardiac function [27,28].  Whether there 
is a diff erence between sitting and prone 
positions in patients’ hemodynamic profi les 
and in requirements of intravenous fl uid 
administration is not known.
Th e objective of this thesis was to 
examine clinically important aspects of 
neuroanesthesia regarding management of 
perioperative hemodynamics in securing 
suffi  cient CPP, transfusion practice 
without compromising blood coagulation, 
and transfusion of blood products in 
neurosurgical patients.
Introduction
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2.1  Cerebral blood ? ow and 
anesthesia
2.1.1  Cerebral blood ? ow and its 
regula? on
Th e human brain, despite its relatively small 
proportion of body size, has high metabolic 
activity, requiring 20% of total basal oxygen 
consumption. Constant CBF is required to 
satisfy the brain’s oxygen needs. Th e brain 
receives 15% of resting cardiac output in 
adults. Th e average cerebral blood fl ow is 
50 ml/100 g/min, however, there is a great 
variation between white and gray matter of 
the brain [29]. A decrease in CBF to 20-25 
ml/100 g/min exposes the brain tissue to 
ischemia. CBF of less than 10 ml/100 g/min 
will result in infarction within a few minutes 
[30-32]. CBF is partly regulated by the brain’s 
complex intrinsic mechanism called fl ow-
metabolic coupling, which optimally matches 
oxygen delivery and consumption. An 
increase in local metabolic activity will result 
in higher CBF in that area [29,33,34]. 
In normal circumstances, CBF 
autoregulation describes the ability of the 
brain to maintain a stable CBF despite 
fl uctuations in cerebral perfusion pressure 
(CPP). CPP is calculated as mean arterial 
pressure (MAP) minus intracranial pressure 
(ICP), or central venous pressure if higher 
[2]. A change in MAP, and consequently in 
CPP, results in changes in cerebrovascular 
resistance (vasodilatation or –constriction 
in cerebral arteries). It is believed that 
autoregulation works when systemic mean 
arterial blood pressure varies between 50 and 
150 mmHg. More recent fi ndings suggest, 
however, that the lower threshold might 
actually be higher. Th ere are variations 
between individuals, and, for example, 
hypertonia shift s the autoregulation curve 
to the right. Outside these thresholds, 
CBF is directly related to CPP [29,35,36]. 
Autoregulation is further divided into 
dynamic and static autoregulation. Dynamic 
autoregulation acts as a rapid response 
to pressure pulsations in systemic blood 
pressure, whereas static autoregulation 
refl ects long-term changes in MAP [29,37,38]. 
Traumatic brain injury (TBI), subarachnoid 
hemorrhage (SAH), brain tumors, and 
various other neurosurgical conditions may 
alter the regulatory mechanics of CBF [39-
41].
PaCO2 is a strong regulator of CBF 
and a linear-like correlation exists between 
CBF and PaCO2. Hyperventilation results 
in lower PaCO2 and vasoconstriction in 
cerebral arteries, thus reducing blood fl ow, 
whereas higher PaCO2 increases CBF by 
vasodilation of the cerebral arteries [42,43]. 
Low PaCO2 value caused by hyperventilation 
may result in brain tissue hypoxemia due to 
intense vasoconstriction [44]. For this reason, 
current neuroanesthesia practice targets 
normoventilation. When treating increased 
ICP, hyperventilation may be used for short 
time periods, but in this case the treatment 
should include appropriate monitoring of 
brain tissue oxygenation [45]. Carbon dioxide 
(CO2) reactivity is disturbed in hypotension 
[25,26]. 
Capnometry is routinely used to monitor 
end-tidal concentration of carbon dioxide 
(EtCO2) with patients under controlled 
ventilation to assess alveolar ventilation and 
PaCO2 [46]. PaCO2 is a strong regulator of CBF 
and even small changes in CBF can produce a 
drastic change in ICP. Th erefore, the accuracy 
of EtCO2 to predict PaCO2 is not suffi  cient 
in neurosurgical patients. Repeated arterial 
blood gas analyses are needed to secure 
optimal ventilation during the perioperative 
phase and also in ICU [47,48]. Th e PaCO2-
EtCO2 diff erence is aff ected by both alveolar 
ventilation and systemic blood circulation. An 
intrapulmonary shunt results in ventilation 
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perfusion mismatch, which increases the 
PaCO2-EtCO2 diff erence [49]. Th e reason 
behind this phenomenon maybe underlying 
pulmonary disease, atelectasis formation, or 
even volatile anesthetics [49-52]. Th e believed 
negative eff ect of volatile anesthetics on 
hypoxic pulmonary vasoconstriction is not, 
however, unanimously supported [53]. Th e 
impact of systemic circulation on the PaCO2-
EtCO2 diff erence is not clear. A linear relation 
has been shown between systemic blood 
pressure and PaCO2-EtCO2 diff erence in ICU 
patients but results in the perioperative phase 
with surgical patients are confl icting [48,54]. 
A positive correlation between changes in 
cardiac output and EtCO2 has been reported 
with surgical patients [55,56].
2.1.2  Intracranial pressure
According to the historic Monro-Kellie 
doctrine, the intracranial space is a fi xed 
volume comprising brain tissue, cerebrospinal 
fl uid, and blood. If the volume of any of 
these components were to increase, it must 
be compensated by a decrease in volume 
of another component [57,58]. As brain 
tissue consists mainly of incompressible 
fl uid, compensatory mechanics are very 
limited, including drainage of CBF to the 
spinal compartment and, to a lesser extent, 
a decrease in intracranial volume of venous 
blood. As indicated by the pressure-volume 
curve, which is not linear but exponential, 
these compensatory mechanisms are able 
to maintain a normal ICP for any change in 
volume less than approximately 100–120 ml, 
but beyond this the ICP will increase abruptly 
and there is a risk of brain tissue herniation 
[59,60].
2.1.3  Anesthe? cs and cerebral blood 
? ow
Th e eff ects of volatile and intravenous 
anesthetics on CBF and cerebral metabolism 
are well-described in the literature [61-63]. 
Volatile anesthetics, although reducing the 
cerebral metabolic rate, is known to cause 
vasodilation in cerebral arteries and also to 
impair autoregulation and fl ow-metabolic 
coupling. Th e severity of the disturbance 
varies between anesthetics and is dose-
related. Sevofl urane is oft en considered the 
best volatile anesthetic because it has the least 
eff ect on vasodilation and autoregulation 
[61]. Propofol, while interfering little 
with autoregulation and CO2 reactivity, 
is a vasoconstrictor, and therefore, with 
its reducing eff ect on brain metabolism, 
is usually the most suitable anesthetic for 
patients with elevated ICP [63]. Animal 
models suggest that both volatile anesthetics 
and propofol also possess neuroprotective 
properties [64-66].
2.2  Periopera? ve ? uid therapy and 
hemodynamic management
2.2.1  Fluid management
In the general surgery population, 
discussion about optimal perioperative fl uid 
application is ongoing [67,68]. Historically, 
a liberal fl uid regimen has been applied to 
guarantee adequate tissue perfusion with 
suffi  cient circulating intravascular volume. 
Substitution of possible fl uid losses from 
fasting, evaporation, and fl uid shift s to a third 
space due to surgery have been ensured with 
liberal administration of fl uids. However, 
recent concerns about potential tissue 
edema, particularly in the intestine, due to 
fl uid overfl ow, and questions regarding the 
existence of a third space have increased 
the popularity of a more restrictive fl uid 
administration [67,69,70]. Controversy 
remains since the terms “liberal” and 
“restricted” are not well-established in the 
literature, and most of the studies involve 
only abdominal surgery patients [71]. It has 
been suggested that fl uid therapy guided 
by the patient’s fl uid responsiveness could 
improve patient outcome [72]. Th is individual 
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goal-directed therapy (GDT) for fl uid 
administration is based on the physiological 
principle of the Frank-Starling law, where 
stroke volume of the heart increases in 
curvilinear response to an increase in 
preload of the heart until the plateau phase 
is reached [73,74]. Earlier, pulmonary artery 
catheter was required for GDT, but today 
less invasive methods measuring fl ow-based 
hemodynamic parameters are available. Th ese 
include transesophageal ultrasound, arterial 
waveform analysis, and pulse contour analysis 
(Vigileo®, Picco®, and Lidco® systems). 
A recent meta-analysis of 29 previously 
conducted studies concludes that preemptive 
hemodynamic monitoring-guided therapy 
improves the outcome of high-risk surgical 
patients [75]. 
No specifi c guidelines exist for 
perioperative fl uid administration in 
neurosurgical patients. Th e goal ought to 
be in preserving adequate perfusion and 
oxygen delivery to the brain and normal 
coagulation capacity. GDT has been adopted 
in neurosurgery as well, and stoke volume 
variation (SVV) has been reported to be 
a good predictor of fl uid responsiveness 
[76,77]. 
2.2.2  Crystalloids and colloids
Crystalloids may vary in osmolarity, but have 
an oncotic pressure of zero, whereas colloids, 
such as albumin and hydroxyethyl starch 
(HES) solutions, contain high molecular 
compounds that create oncotic forces and 
add overall colloid osmotic pressure [67]. 
Crystalloids may vary in osmolarity, but have 
an oncotic pressure of zero, whereas colloids, 
such as albumin and hydroxyethyl starch 
(HES) solutions, contain high molecular 
compounds that create oncotic forces and add 
overall colloid osmotic pressure [67]. 
Crystalloids’ ability to increase 
intravascular volume is limited because 
these solutions will distribute evenly within 
the extracellular space. A reported 20% of 
normal saline and 17% of lactated Ringer’s 
solution remain in the intravascular space 
[67,78]England. In addition, 0.9% saline, 
or “normal saline” as it is oft en called, has 
an equal concentration of sodium and 
chloride ions (154 mmol/l), making it slightly 
hypertonic compared with physiological 
plasma sodium levels. Saline solutions are 
associated with a risk of hyperchloremic 
acidosis [79-81]. Chloride concentration 
has been reduced in buff ered solutions, such 
as Ringer’s acetate (RAC), where chloride 
concentration is 103 mmol/l, thus decreasing 
the risk of hyperchloremic acidosis. RAC 
resembles extracellular fl uid in terms of 
ion concentrations [82]. If RAC solutions 
are used in neurosurgical patients, their 
relatively low sodium concentration must be 
considered. Plasma osmolarity aff ects water 
movement through BBB, and reduction in 
plasma osmolarity may lead to increased 
brain edema [3].
Colloids, including human-derived 
albumin and synthetic solutions such 
as gelatin, dextran, and hydroxyethyl 
starch (HES), have been used to increase 
intravascular volume more effi  ciently than 
crystalloids [83]. Oncotic force and duration 
of volume expanding eff ect depend on 
molecular size of the solutions [83]. HES 
solutions have developed from earlier high 
molecular weight and molar substitution to 
more rapidly degradable lower molecular 
weight and low degree of substitution 
solutions such as HES 130/0.4 [84].
Regarding intraoperative fl uid 
administration, there has been an ongoing 
vigorous debate about whether colloids are 
more eff ective than crystalloids in increasing 
hypovolemic patients’ intravascular volume 
and stroke volume (SV) of the heart [8-10,85-
87]. Recent fi ndings with ICU and surgical 
patients show that the diff erence between the 
two solution types is notably smaller than 
earlier believed [10,88,89], being 1.3- to 1.6-
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fold in favor of colloid solutions. However, in 
situations where acute bleeding occurs a fi ve-
fold amount of crystalloids compared with 
colloids has been recommended to replace 
blood loss [78].
Crystalloids and artifi cial colloids as well 
as albumin have all historically been used to 
treat neurosurgical patients. When lactated 
Ringer and HES solutions were compared 
regarding their eff ect on brain relaxation and 
brain metabolism, no evidence was found that 
one solution type would be more benefi cial 
than the other [90]. 
Dilution caused by administration of 
normal saline induces a hypercoagulable state, 
and thus, is not associated with decreased 
blood coagulation [91].  Data concerning the 
eff ect of RAC solution on blood coagulation 
are limited, but an experiment in vivo shows 
that a dilution of over 50% is needed to impair 
coagulation [92].  
All artifi cial colloids may interfere 
negatively with blood coagulation [5-7,93-
95]. Th e eff ect of HES solutions on blood 
coagulation depends on the molecular weight 
and substitution degree of the solutions, 
with third-generation HES 130/0.4 having 
the smallest eff ect [96]. Albumin has been 
considered to have a minimal eff ect on blood 
coagulation, but when administered in large 
doses can interfere with coagulation. Th e 
eff ect might be partly explained by dilution 
[7,97].
Use of hydroxyethyl starch solutions 
has been questioned since the publication of 
two large randomized trials comparing HES 
solution with crystalloids in fl uid resuscitation 
[11,12]. Increased mortality and likelihood 
of renal replacement therapy among severe 
sepsis patients were associated in the 6S-trial 
with the use of HES solutions compared with 
RAC solution [11]. One study concluded that 
in a heterogeneous ICU patient population no 
diff erence in mortality existed, but patients 
who received fl uid resuscitation with HES 
needed renal replacement therapy more oft en 
than patients receiving saline [12]. Another 
multicenter trial repeated the result of an 
association between increased risk of kidney 
failure and HES with ICU patients, but no 
diff erence in mortality was found [98]. 
Safety of HES in perioperative care 
remains partly unclear due to the lack of 
large randomized trials. However, two meta-
analyses of HES use in surgical patients 
found no association between increased risk 
of kidney failure and use of HES [99,100] or 
between increased mortality and use of HES 
[100].
Albumin is not associated with increased 
risk of adverse events in ICU and septic 
patient populations [88,101]. However, the 
post-hoc analysis of the SAFE study revealed 
that patients with traumatic brain injury 
(TBI) had higher mortality if they had been 
treated with albumin and saline instead of 
only saline [102].
Th e consensus statement of the European 
Society of Intensive Care Medicine task force 
does not recommend the use of low molecular 
weight HES and gelatin solutions in patients 
with severe sepsis or kidney injury or colloids 
in general in patients with TBI [103].
2.2.3  Mannitol and hypertonic saline
Osmotherapy is oft en used in treatment 
of elevated ICP in patients suff ering 
from TBI, brain tumor, SAH, or other 
intracranial volume-occupying lesions [104]. 
Traditionally, mannitol has been the agent 
of choice, but HS has proved to be a worthy 
alternative [105-108]. HS is equally eff ective 
or even better than mannitol in reducing brain 
swelling, and consequently ICP, in patients 
undergoing craniotomy [19-22,109,110]. A 
recent retrospective review evaluating HS 
and mannitol during ICU stay concluded 
that HS was more eff ective in cumulative 
and daily ICP burdens aft er severe TBI [111]. 
However, due to the heterogeneity of the 
studies regarding osmolarity and volumes 
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of the solutions and the lack of randomized 
controlled trials, no defi nite conclusions 
about the superiority of HS to mannitol in 
treating ICP can be made. 
Earlier in vitro reports indicate that both 
mannitol and HS possess features that may 
jeopardize blood coagulation [6,23,24,112]. 
Mannitol alone reduces clot strength and 
when combined with hydroxyethyl starch 
the eff ect is even more profound [6]. HS at 
diff erent concentrations (3–7.5%) impairs 
coagulation process by inhibiting fi brin 
formation and platelet function [23,24,112]
Both solutions have clinically important 
side-eff ects. Contrary to HS, mannitol 
is associated, particularly aft er repeated 
doses, with acute renal failure [113-116]. As 
mannitol has a strong diuretic eff ect, it may 
also cause disturbances in a patient’s fl uid 
balance and electrolyte levels, consequently 
requiring adjustments in general fl uid 
administration [117]. Moreover, the osmotic 
response to mannitol treatment is not 
entirely predictable, and there is a risk of 
unwanted rebound increase in ICP, especially 
aft er repeated doses. Th is phenomenon is 
believed to result from intact BBB allowing 
leakage of mannitol into brain tissue [118-
120]. Variations in plasma sodium levels are 
evident when using mannitol or HS. While 
mannitol causes hyponatremia, the use of HS 
increases plasma sodium levels and can result 
in hyperchloremic acidosis [22].
2.2.4  Red blood cells, platelets, and 
fresh frozen plasma
A recent review evaluating studies that have 
tried to establish hemoglobin level thresholds 
for red blood cell (RBC) transfusion in 
neurosurgical patients concluded that the 
optimal hemoglobin level remains unclear 
[13]. Challenges are posed by the vast 
variety of neurosurgical conditions and the 
requirement possibly not being the same 
perioperatively as during intensive care [13]. 
It is currently believed that neurointensive 
care patient populations would benefi t from 
slightly higher hemoglobin levels than general 
ICU patients because the brains’ strict oxygen 
requirements in the former group make it 
vulnerable to hypoperfusion and hypoxia 
[121].
SAH patients with a higher hemoglobin 
level may have a better outcome, but the 
optimal hemoglobin level remains unknown. 
Adding to the complexity of the issue, red 
blood cell transfusion itself seems to be 
associated with worse neurological outcome 
and increased risk of vasospasm in SAH 
patients, although confl icting results have 
also been reported [122-128]. RBCT during 
ICU stay of SAH patients is also associated 
with other medical complications such as 
pneumonia [129]. Th e age of transfused 
RBCs has recently received increased interest, 
although thus far RBC age has not been 
shown to have an eff ect on outcome of SAH 
patients receiving RBCT [123,130]. Th e 
transfusion rate for RBCs during surgery for 
ruptured arterial aneurysm varies between 
5.6% and 27.2% [131-133].
No specifi c thresholds for transfusion 
of platelets or fresh frozen plasma (FFP) are 
available due to insuffi  cient evidence. 
Massive bleeding during neurosurgery 
can occur abruptly. Guidelines are lacking for 
the treatment of neurosurgical patients, both 
adult and pediatric patients, during massive 
bleeding. However, current guidelines for 
trauma patients recommend early use of RBC, 
FFP, and platelets [134-136]. Historically, 
RBCs were administered fi rst together with 
crystalloids, but today it is suggested that FFP 
and platelets be given together with RBCs 
in a volume ratio of 1:1:1 [137].   Decreased 
fi brinogen concentration is an important 
factor in impaired coagulation capacity [138]. 
Recommendations for blood product use 
in pediatric ICU patients are conservative, 
and blood product transfusion is advised 
only aft er coagulation defi cit is confi rmed 
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by laboratory testing [139]. Th is treatment 
approach is not suitable for pediatric 
neurosurgical patients, in whom abrupt 
bleeding during surgery is possible and can 
quickly result in severe hypovolemia. In this 
situation, any laboratory test would be too 
slow to guide fl uid administration.
2.2.5  Periopera? ve hemodynamic 
control
In general, stable hemodynamics is 
required during the perioperative phase in 
neurosurgery to guarantee suffi  cient CPP 
pressure and to minimize intraoperative 
bleeding [15]. Th e blood pressure target 
must be adjusted according to the underlying 
pathology. In TBI, patients oft en have an 
increased ICP, thus requiring higher CPP 
for optimal oxygen delivery. Aft er surgical 
opening of the dura, the oft en associated 
decrease in blood pressure should be 
monitored to prevent an excessive decrease in 
blood pressure [140]. 
Patients with SAH due to ruptured 
arterial aneurysm are at high risk of 
re-bleeding [141]. Th erefore, good 
hemodynamic control is essential and any 
peaks in blood pressure should be avoided 
throughout the perioperative period until 
the aneurysm is safely occluded from the 
circulation [142,143]. Again, if ICP is 
increased, blood pressure should be adjusted 
accordingly. Opening of the dura will 
decrease the transmural pressure diff erence of 
the aneurysm wall and may lead the a rupture 
of an aneurysm if systemic blood pressure is 
too high [143]. During temporary clipping 
an increase of systemic blood pressure may 
be considered to optimize oxygen supply 
through collateral blood fl ow [142,143].
2.2.6  Adenosine
Adenosine is an endogenously occurring 
nucleoside. It has a very short negative eff ect 
on cardiac sinoatrial and atrioventricular 
nodes, resulting in decreased heart rate 
and prolonged conductance. Adenosine 
acts on cardiac A1 receptors, causing 
hyperpolarization by increased outward fl ux 
of potassium, and reduces intracellular cyclic 
adenosine monophosphate. Th is further 
inhibits calcium entry into the cell. When 
administered intravenously, adenosine has 
a quick onset of action and a short half-life 
[144-146]. Th e duration of the occurring 
asystole is dose-dependent [147].
Adenosine has been traditionally used in 
cardiology for treatment of supraventricular 
tachyarrhythmia [146]. In the surgical fi eld, 
adenosine-induced asystole was fi rst applied 
in cardiac bypass surgery and also in thoracic 
surgery to facilitate precise deployment of 
stent graft s [148,149]. 
In the fi eld of neurosurgery, adenosine-
induced transient asystole was fi rst described 
in endovascular embolization of cerebral 
arteriovenous malformation. Soon aft er, the 
fi rst report of adenosine use in surgery for 
cerebral arterial aneurysm was described in a 
case where repeated dosing of adenosine was 
used to facilitate clipping of a basilar arterial 
aneurysm [17,150]. Clinical experience has 
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Figure 1 Example of 
adenosine- induced 
cardiac arrest seen in 
electrocardiography 
(fi gure used with 
the permission of 
the copyright holder 
Hanna Tuominen).
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shown that adenosine-induced cardiac arrest 
is a valuable tool in facilitating clipping of 
an aneurysm, especially in situations where 
proximal occlusion of the feeding artery 
by temporary clipping is not possible or in 
the event of intraoperative rupture of an 
aneurysm (Figure 1). 
2.3  Periopera? ve coagula? on
2.3.1  Measurement of coagula? on
A postoperative hematoma is a potential life-
threatening complication aft er intracranial 
surgery and is frequently associated 
with a poor outcome and even death of 
neurosurgical patients [4]. 
Postoperative bleeding complications 
are oft en related to perioperative coagulation 
disturbance, and therefore, it is essential 
to detect pre-existing hemostatic problems 
and to preserve normal coagulation capacity 
throughout neurosurgical procedures. 
Th e reason for underlying disturbance is 
oft en multifactorial and can be related to 
medications interfering with the coagulation 
system or platelet function or to a defi ciency 
in endogenic coagulation factor production 
[151]. Patients can develop an acute 
coagulation disturbance perioperatively due 
to blood loss, dilution, and consumption 
of coagulation factors or, in rare cases, 
disseminated coagulopathy. On the other 
hand, hypercoagulopathy is oft en detected in 
patients undergoing craniotomy, and risk of 
postoperative thromboembolic complications 
is increased [151-153].
Although important to screen, normal 
preoperative laboratory data do not guarantee 
that the patient’s coagulation capacity is 
normal. For example, factor VIII defi ciency, 
which has been shown to contribute to 
postoperative bleeding problems, might go 
unnoticed because it is not detected by partial 
thromboplastin time (PTT) or prothrombin 
time (PT) [151]. Also, platelet count remains 
normal even if platelets are dysfunctional due 
to antiplatelet drugs. Careful preoperative 
evaluation and risk assessment for bleeding 
are important, as is additional coagulation 
testing when indicated [151].    
2.3.2  Thromboelastometry
In the perioperative setting, traditional 
coagulation tests are oft en too slow to guide 
transfusion of fl uids and blood products 
[154]. Contrary to these traditional laboratory 
tests, visco-elastic whole-blood point-of-care 
testing allows quick and dynamic evaluation 
of the entire coagulation process and also 
enables intrinsic and extrinsic coagulation 
pathways to be distinguished from pure fi brin 
formation [155,156]. 
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Figure 2 Sample of 
thromboelastometry 
tracing and 
parameters 
(reprinted and 
modifi ed from 
www.practical-
haemostasis.com 
with permission of 
the website owner 
David Perry). 
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Th romboelastography was developed 
already in 1948, but the fi rst clinical 
report of its use came in the 1980s 
[156,157]. Development from the original 
thromboelastometry has led to commercially 
available visco-elastic whole-blood 
analyzers: thromboelastography (TEG®), 
thromboelastometry (RoTEM®), and 
Sonoclot® [158]. 
In thromboelastometry analysis 
(RoTEM®), citrated blood is combined with 
the desired reagent in a cup to start the 
coagulation test. Th e cup is then placed under 
a slowly oscillating pin.
Th e analyzer measures the changes in 
elasticity of the developing clot. Usually 30 
minutes is enough for the analysis, but the 
coagulation process can be investigated at all 
times during the analysis, as the development 
of the forming clot is graphically displayed 
and the start of clot formation can occur 
within minutes. Besides the visual estimation 
of the graphic display of the coagulation 
process, several numeric values can be 
obtained and normal reference ranges have 
been established [156] (Figure 2). 
• Clotting time (CT) describes the time 
from start of analysis until start of clot 
formation. Heparin eff ect or lack of 
coagulation factors can be the reason 
behind increased CT.  In hypercoagulable 
state, CT is decreased.
• Clot formation time (CFT) and alpha 
angel describes the velocity of the 
forming clot. Decreased values can be 
seen in platelet or fi brinogen defi ciency.   
• Maximum clot fi rmness (MCF) is the 
strength of the developed clot until the 
start of potential fi brinolysis.  
• Maximum lysis (ML) shows the decrease 
in clot strength aft er MCF is reached. 
Increased lysis is an indication of 
hyperfi brinolysis.
Diff erent reagents are used in RoTEM® 
analysis. ExTEM® includes tissue 
thromboplastin and screens the extrinsic 
pathway [158]. FibTEM® is similar to 
ExTEM®, but has cytochalasin added to inhibit 
platelet function, thus allowing estimation of 
fi brinogen contribution to clot strength [158]. 
ApTEM® includes aprotinin to detect possible 
increased fi brinolysis relative to ExTEM® 
[158]. InTEM® is added with contact activator 
and screens the intrinsic pathway [158].
A limitation of thromboelastometry in 
perioperative settings is that it is unable to 
detect platelet dysfunction caused by platelet 
aggregation inhibitors such as acetylsalicylic 
acid and clopidogrel or von Willebrand’s 
disease [159,160]. Other testing methods 
designed for measuring platelet function 
should be used in these cases [160].
A meta-analysis that evaluated the use 
of RoTEM® or TEG® in a bleeding trauma 
patient population stated that they might 
be useful in detecting early coagulopathy 
[161]. Whether they have impact on blood 
product consumption or mortality remains 
unclear [161]. In the perioperative phase, 
thromboelastometry-guided treatment has 
reduced blood product use in cardiac surgery 
and bleeding burn patients [162,163]. 
Reports concerning the use of 
thromboelastometry in neurosurgical patients 
have concentrated on hypercoagulability, 
which is oft en associated with patients 
undergoing craniotomy [152,153], or on 
underlying coagulation abnormality [164].
2.4  Pa? ent posi? oning in 
neurosurgery
To achieve an optimal surgical approach, 
diff erent patient positions have been used in 
neurosurgery. Patient can be operated on in 
supine or prone position, but also in lateral or 
sitting or semi-sitting position [165]. 
Neurosurgery in sitting position was 
more popular in the 1970s and 1980s than it 
is today. Still now, there is a great variation 
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in which centers and in which countries 
sitting position is used, oft en depending on 
tradition and the experience of the individual 
neurosurgeon [166]. Sitting position off ers 
advantages in certain types of neurosurgery 
and is oft en preferred when operating on 
lesions in the posterior cranial fossa [167]. 
When the patient is in the sitting position, 
ICP is decreased and the operating fi eld 
is clearer due to gravity forcing blood and 
cerebrospinal fl uid downwards. With the 
anatomical approach, surgery in a sitting 
position is associated with lesser risk of 
cranial nerve damage [168]. A major concern, 
posing challenges for both the neurosurgeon 
and anesthesiologist, is venous air embolism 
(VAE). Reported incidence varies between 
1.6% and 50%, the incidence being lower in 
the semi-sitting position [85,169-171]. VAE 
is best detected with precordial Doppler 
ultrasound, but also decrease in EtCO2 
will reveal 80% of the VAEs detected by 
ultrasound [172]. 
Th e prone position provides good surgical 
access to the posterior head, neck, and spinal 
column, and it is therefore used for spinal 
surgery. Th e prone position is also possible 
for some parietal, occipital, and suboccipital 
craniotomies [28]. Some operations can 
be performed in both prone and sitting 
positions, in which case the decision is made 
according to the neurosurgeon’s preference. 
Anesthesiological aspects should also be 
taken into consideration [27].
Neurosurgery in general anesthesia 
both in prone and sitting positions exposes 
the patient to hemodynamic alterations, i.e. 
hypotension and changes in cardiac function, 
compared with the supine position [27,173-
177].  
Th e sitting position causes hypotension 
and a decrease in cardiac function, posing 
a challenge in providing suffi  cient CPP and 
oxygen delivery to the brain [173,174,178]. 
Hemodynamic changes can partly be 
explained by pooling of venous blood to the 
lower extremities. [173]. Carefully planned 
position, preemptive fl uid optimization, 
and use of an anti-gravity suit may diminish 
changes in patients’ hemodynamics. CI, 
SVI, and SVV before positioning may have 
a predictive value for hypotension occurring 
aft er positioning [179]. A decrease in cardiac 
function is also associated with surgery in the 
prone position. Decreased cardiac function 
is believed to result from reduced venous 
return and ventricular compliance of the 
heart [176,177].  Hemodynamic changes may 
be prevented by adequate fl uid replacement 
prior to positioning [176].
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Aims of the Study
3.  AIMS OF THE STUDY
Th is study examines clinically relevant aspects of neuroanesthesia regarding cerebral blood fl ow 
and perfusion pressure, blood coagulation, and transfusion of blood products in neurosurgical 
patients.
Specifi c aims were as follows:
 
1. To evaluate perioperative transfusion rates of RBC, platelets, and FFP in patients operated 
on for ruptured cerebral arterial aneurysm.
2. To identify potential risk factors for RBCT and its eff ect on patient outcome.
3. To investigate the incidence of cardioplegia caused by intraoperative use of adenosine 
during surgery of ruptured cerebral arterial aneurysm.
4. To examine coagulation during replacement of blood loss with FFP and RBCs.
5. To compare in vitro the eff ect that equimolar and equivolemic solutions of mannitol and HS 
have on blood coagulation.
6. To characterize the impact of arterial blood pressure change on PaCO2-EtCO2 in patients 
anesthetized for craniotomy. 
7. To compare the intraoperative requirement of HES 130/0.4 and RAC to achieve stable 
hemodynamics guided by stroke volume measurement between neurosurgery in the prone 
and sitting positions.
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4.  MATERIALS AND METHODS
Th is study was carried out at the Department of Anesthesiology and Intensive Care and 
the Department of Neurosurgery of Helsinki University Hospital, Finland. Seventy-two 
neurosurgical adult and 2 neurosurgical pediatric patients and 10 healthy volunteers participated 
in Studies III-V. Study VI included 58 patients previously recruited for two earlier studies [10,85]. 
Additionally, Studies I and II included a retrospective review of the medical records of 488 plus 
1014 patients (partly the same patients) (Table 1).
Th e Helsinki University Central Hospital Scientifi c board approved all studies. In addition, 
the Ethics Committee of the hospital district approved Studies IV-VI. All patients and volunteers 
in Studies IV-VI gave their informed consent to participate.
Table 1 Study characteristics. 
N Subjects Study design Intervention Primary end-point
I 488 Neurosurgical 
patients
Retrospective None Incidence of periop-
erative transfusion 
of blood products in 
patients operated on 
for ruptured cerebral 
arterial aneurysm
II 1014 Neurosurgical 
patients
Retrospective None Incidence of perioper-
ative use of adenosine 
in patients operated 
on for ruptured cere-
bral arterial aneurysm
III 2 Pediatric pa-
tients
Clinical report None Coagulation assessed 
with thromboelasto-
metry (Rotem®)
IV 10 Healthy volun-
teers
In vitro experi-
ment
10 and 20 vol% 
dilution of blood 
with mannitol 15%, 
NaCl0.9%, 2.5%, 
and 3.5%
Coagulation assessed 
with thromboelasto-
metry (Rotem®)
V 72 Neurosurgical 
patients
Prospective None Eff ect of systemic 
blood pressure chang-
es on PaCO2-EtCO2 
diff erence
VI 30+28 Neurosurgical 
patients
Post-hoc analysis 
of two separate 
prospective trials
SV-directed admin-
istration of RAC 
and HES 130/0.4
Volumes of RAC and 
HES in prone vs sit-
ting position
PaCO2 = arterial carbon dioxide partial pressure
EtCO2 = end-tidal concentration of carbon dioxide
RAC = Ringer’s acetate
HES = hydroxyethyl starch
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4.1  Studies I and II
Anesthesia reports of the patients operated 
on for ruptured cerebral arterial aneurysm 
at the Department of Neurosurgery of 
Helsinki University Hospital between 2006 
and 2009 (Study I) and at the neurosurgical 
departments of Helsinki University Hospital 
and Turku University Hospital between 
2003 and 2008 (Study II) were reviewed to 
identify patients who had received blood 
products (Study I) or adenosine (Study II) 
intraoperatively. 
Aft er identifying patients (Study I) who 
had received RBC, platelets, or FFP during 
preparation for surgery, intraoperatively, or 
during the immediate postoperative period 
(within 24 hours of surgery), transfusion rates 
of RBC, platelets, and FFP were calculated. 
Th ese patients were then compared with 
patients listed in the general Helsinki 
database of aneurysmal SAH. A multiple 
regression model was created to identify 
explanatory factors for RBCT and outcome 
where GOS was divided into two categories: 
good outcome (GOS 4-5) and poor outcome 
(GOS 1-3).
In Study II, the dose of adenosine, 
hemodynamics before and aft er its 
administration, and length of stay in intensive 
care unit (ICU) and hospital were recorded. 
In addition, the patients were grouped 
according to discharge status from hospital 
(dead or alive) and according to outcome 
(good outcome, GOS 4-5; poor outcome, 
GOS 1-3).
4.2  Study III
Th is clinical report included two previously 
healthy children scheduled for craniotomy 
due to brain tumor. A 10-month-old boy had 
been diagnosed with a richly vascularized 
tumor extending to the mesencephalon 
and hypothalamus (Figure 3). Similarly, in 
a 5-month-old boy, magnetic resonance 
imaging (MRI) had revealed a massive tumor 
in the left  pontocerebellar area causing 
pressure to the brainstem (Figure 4). Massive 
intraoperative bleeding was anticipated due to 
the nature of the brain tumor in both patients.
In addition to crystalloid solution, FFP 
infusion was started aft er the induction 
of anesthesia. RBCs were administered 
according to intraoperative bleeding. Besides 
traditional laboratory tests (hemoglobin, 
hematocrit, platelet count, and PT%), a four-
channel thromboelastometry device (Rotem®, 
Pentafarm AG, Basle, Switzerland) was used 
for coagulation analysis. Four diff erent 
thromboelastometry tracings were used: 
Intem® (intrinsic pathway), Extem® (extrinsic 
pathway), Fibtem® (platelet function 
inhibition by cytochalasin D), and Aptem® 
(added aprotinin to 
detect hyperfi brinolysis). 
Th ese tests were carried 
out pre-, intra-, and 
postoperatively and on 
the morning of the fi rst 
postoperative day.
Figure 3 MRI before (A) 
and aft er (B) surgery.
25
Materials and Methods
Figure 4 MRI before (A) 
and aft er (B) surgery.
4.3  Study IV 
Venous blood samples 
taken from 10 previously 
healthy volunteers were 
diluted with the study 
solutions to make 0, 
10, and 20 vol% fi nal 
concentrations. Th e 
study solutions were 
0.9% saline (Natriumklorid Braun® 9 mg/ml, 
reported osmolarity 300 mOsm/l), 2.5% saline 
(1 part Natriumklorid Braun® 234 mg/ml + 
13.1 parts Natriumklorid Braun® 9 mg/ml), 
3.5% saline (1 part Natriumklorid Braun® 234 
mg/ml + 7.6 parts Natriumklorid Braun® 9 
mg/ml), and 15% mannitol (Mannitol Braun® 
150 mg/ml infusion fl uid). Th e manufacturer 
of Mannitol Braun® 150 mg/ml infusion fl uid 
reports that theoretical osmolarity of the fl uid 
is 825 mOsm/l. Calculated osmolarity for 
2.5% saline is 830 mOsm/l and for 3.5% saline 
1160 mOsm/l.
Two four-channel thromboelastometry 
devices (Rotem®, Pentafarm AG, Basel, 
Switzerland) were used for the coagulation 
analysis of the diluted samples and a control 
sample. Extrinsic ROTEM (tissue coagulation 
activator, EXTEM®) and fi brinogen ROTEM 
(FIBTEM®) were used for the analysis. 
Developments in the coagulation process were 
recorded over a 30-min period. Measured 
coagulation parameters for ExTEM® were 
clotting time (CT), clot formation time 
(CFT), maximum clot fi rmness (MCF), and 
alpha angle (clot formation rate). Only MCF 
was measured in FibTEM® analysis. 
4.4  Study V
Seventy-two adult patients scheduled 
for craniotomy at the Department of 
Neurosurgery, Helsinki University Hospital, 
were enrolled in this study. Patients with a 
history of pulmonary or cardiac valve disease, 
a decreased state of consciousness, or who 
already had an endotracheal tube or had 
required emergency surgery were excluded 
from the trial.
Th e change of MAP between intubation 
and attachment of the patient’s head to a head 
frame (measured at 5-min intervals and prior 
to attachment) was calculated. Th e measured 
diff erence between PaCO2 and EtCO2 at the 
time of pinning of the head was compared 
with the calculated diff erence in MAP.
4.5  Study VI
Study VI consisted of 58 patients (30+28) 
from two previously conducted, separate 
prospective trials comparing stroke volume-
directed administration of hydroxyethyl 
starch (HES 130/0.4) and Ringer’s acetate in 
prone [10] and sitting [85] positions during 
neurosurgery. Th e results of diff erences 
between the study fl uids in achieving stable 
hemodynamics within one surgery position 
and also the eff ect that these two fl uids have 
on patient blood coagulation measured by 
Rotem® analysis have been reported earlier 
[10,85]. 
Patients younger than 18 years with 
body mass index (BMI) > 36 kg/m2 in the 
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prone position or > 40 kg/m2 in the sitting 
position, congestive heart failure, other than 
sinus rhythm on electrocardiography (ECG), 
renal failure (plasma creatinine > 120 μmol/l), 
hepatic failure, anemia (hemoglobin < 100 
g/l), and thrombocytopenia (platelet count 
< 100x109/l) were excluded. Additionally, 
expected use of mannitol in the sitting 
position resulted in exclusion. 
Before anesthesia induction, a basal 
Ringer’s acetate (RAC) infusion was initiated 
at a rate of 3 ml/kg/h (an additional 40 mmol/l 
of NaCl was added to RAC basal infusion of 
patients in sitting position).
Both study sequences (prone and sitting 
position) had the same protocol for the study 
fl uid administration. Patients were randomly 
assigned (using closed envelopes drawn in 
sequential order by the primary investigators) 
in blocks of three to receive one of the 
following study solutions:
1.  6% HES solution (Voluven®; 60 mg/
ml, average molecular weight 130 kDa, 
molar substitution ratio 0.4, pH 4.0–
5.5, contents Na+ 154 mmol/l, Cl- 154 
mmol/l; Fresenius Kabi, Bad Homburg, 
Germany) (HES group, n = 15 in prone 
position + 15 in sitting position).
2.  Ringer’s acetate solution (Ringer-acetate®, 
pH 6.0, contents Na+ 131 mmol/l, Cl- 112 
mmol/l, K+ 4 mmol/l, Ca++ 2 mmol/l, 
Mg++ 1 mmol/l, CH3COO- 30 mmol/l; 
Fresenius Kabi) (RAC group, n = 15 in 
prone position + 15 in sitting position).
Aft er anesthesia induction, while lying 
supine, all patients received an initial 200 
ml bolus of the study fl uid over 2–4 min, 
and hemodynamic measurements were 
performed before and 3 min aft er the 
administration of study fl uid. A new bolus of 
100 ml over 2–4 min was given immediately 
aft er the hemodynamic measurements, until 
stroke volume (SV) did not increase more 
than 10%. Th e hemodynamic measurements 
were performed 3 min aft er each bolus.
Th ereaft er, patients were positioned 
for surgery. Registration of hemodynamic 
parameters took place at 5-min intervals 
during surgery. If SV decreased more than 
10% from the value obtained in the supine 
position, further study fl uid boluses of 100 ml 
were administered. If the SV did not increase 
with three consecutive boluses, the volume 
expansion was stopped and the patient was 
considered a non-responder. Hemodynamic 
parameters were registered also at the end of 
surgery and aft er the patient was placed in the 
supine position.
Th e target MAP was 60 mmHg or higher 
at the brain level. Boluses of phenylephrine 
(0.05–0.1 mg) or ephedrine (5–10 mg) 
were given if MAP was below 60 mmHg 
despite the study fl uid administration. A 
phenylephrine infusion was started whenever 
MAP remained below 60 mmHg for more 
than 5 min.
Basal infusion of RAC (with NaCl 
supplement if required) continued at a rate 
of 1 ml/kg/h until the fi rst postoperative 
morning. Registration of urine output and 
fl uid balance took place at pre-determined 
intervals. 
Aft er data combination, two-way 
ANOVA was used to test diff erences in 
stroke volume-directed fl uid administration 
between the two diff erent positions (surgery 
in prone vs. sitting position) and to determine 
whether one of the study fl uids was more 
benefi cial than the other.  
4.6 Anesthesia and monitoring 
(Studies V and VI)
Anesthesia was induced in the supine 
position with fentanyl and either thiopental 
or propofol. Endotracheal intubation was 
facilitated by either suxamethonium or 
rocuronium. Anesthesia was maintained with 
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sevofl urane with or without nitrous oxygen 
(N2O) and air and additional fentanyl boluses 
or a continuous infusion of propofol and 
remifentanil in patients operated on in prone 
position and with a continuous infusion 
of propofol in patients in sitting position 
with the permission to use sevofl urane to 
treat severe hypertension. Aft er tracheal 
intubation, volume-controlled mechanical 
ventilation without positive end-expiratory 
pressure (PEEP) was initiated. In Study V, 
tidal volume was set to 8-10 ml/kg body 
weight and rate of ventilation to 10-15/min, 
targeting normoventilation (PaCO2 4.5-5.0 
kPa). In Study IV, ventilator settings were 
determined by the attending anesthesiologist.
Monitoring of anesthesia prior to 
intubation included noninvasive arterial 
blood pressure, ECG (lead II), and arterial 
saturation of oxygen (SpO2). Aft er tracheal 
intubation, monitors of nasopharyngeal 
temperature, side-stream spirometry 
(Side stream®, Datex-Ohmeda Inc., GE 
Healthcare, Madison, WI, USA), and end-
tidal concentration of carbon dioxide were 
applied. Additionally, a 20G arterial catheter 
(Becton Dickinson, Temse, Belgium or 20 BD 
Arterial Cannula, Singapore) was inserted 
into the radial artery for invasive monitoring 
of arterial pressures and to obtain blood 
samples. 
To continuously monitor cardiac output 
(CO), cardiac index (CI), stroke volume (SV), 
stroke volume index (SVI), and stroke volume 
variation (SVV) in Study VI, the Vigileo 
System (Edwards Lifesciences, Irvine, CA, 
USA) with soft ware version 3.02 was applied 
by connecting it into an arterial line with a 
pressure transducer set (FloTrac; Edwards 
Lifesciences) zeroed at the heart level. For 
patients operated on in sitting position, an 
additional set was applied and zeroed at the 
level of the foramen Monroi for measurement 
of systolic, diastolic, and mean arterial 
pressure.
4.7  Pa? ent posi? oning (Study VI)
In prone position, bilateral chest supports 
were used and the patient’s head was placed 
on a headrest (Prone View Protective Helmet 
System; Dupaco, Oceanside, CA, USA), or 
fi xed with the Sugita pin head-holder device 
(Sugita Head Frames; Mizuho America, 
Union City, CA, USA). In sitting position, 
patients were dressed in an antigravity suit, 
the patient’s upper body was elevated 50–100° 
and the head was attached to a head-holder 
device (Mayfi eld; Integra Life Sciences, 
Plainsboro, NJ, USA) and tilted forward 
20–30° with the patient sitting with knees 
slightly fl exed on a pillow. 
4.8  Sta? s? cal analyses
Th e statistical analyses for all data were 
done with the following statistical soft ware: 
SYSTAT 10.2 statistical package (SYSTAT 
Soft ware, Inc., San Jose, CA, USA), IBM SPSS 
Statistics®, version 21, StatView PowerPC 
version 5.0 (SAS Institute Inc., Cary, NC, 
USA), or the statistician’s personal non-
commercial soft ware.
Th e descriptive statistics are shown as 
mean ± SD, as median (range), or as numbers 
(percentage). Th e diff erences between the 
groups were analyzed by t-test (Study II) or 
ANOVA (Studies IV-VI followed by t-test 
or Tukey–Kramer for paired comparisons 
if needed). Fisher’s exact test was used for 
categorical variables and Mann-Whitney 
U-test for continuous variables for group 
comparison (Study I). 
Linear regression was used to detect 
a possible correlation between change in 
MAP and PaCO2-EtCO2 diff erence (Study 
V). Logistic regression and odd ratios were 
used for assessment relationships between 
the two outcome variables and each main 
study variable (Study I). Tested variables 
of risk factors for RBCT were hemoglobin 
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concentration, platelet count, plasma 
prothrombin time value (P-PT, %), WFNS 
and Fisher grades, aneurysm location, 
intraoperative aneurysm rupture, aneurysm 
size, and gender. For outcome analysis, 
variables were intraoperative rupture of an 
aneurysm, RBCT, WFNS and Fisher grades, 
age, preoperative hemoglobin, and aneurysm 
size. Variables independently associated with 
study outcomes with a p-value of less than 
0.1 in univariate analysis were included in 
multivariable logistic regression analysis. 
Additionally, a propensity score was calculated 
using covariates that were associated with 
intraoperative red blood cell transfusion, and 
this was added to the multivariate analysis 
assessing the outcome as a covariate. Variance 
infl ation factor was calculated in order to 
detect possible multicollinearity between the 
covariates (Study I).
Th e number of volunteers in Study IV 
was based on the calculation that in a cross-
over study setting eight volunteers would be 
needed to discover a greater than 1 standard 
deviation (SD) diff erence in MCF between 
the equiosmolar HS and mannitol groups of 
similar vol% dilution (alpha error 0.05). 
P-value less than 0.05 was considered 
signifi cant in all analyses.
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All patients initially included in Studies 
III and IV completed the study. Study V 
consisted of patients enrolled earlier for two 
separately conducted studies [10,85].
5.1  RBC, FFP, and platelet 
transfusion
Seventy of 488 patients operated on for 
ruptured cerebral arterial aneurysm received 
blood products during the perioperative 
phase (I). Transfusion rates for RBC, FFP, 
and platelet transfusion intraoperatively 
were 7.6% (37/488), 3.1% (15/488), and 1.2% 
(6/488), and postoperatively 3.5% (17/488), 
1.6% (8/488), and 0.9% (4/488), respectively. 
Five patients received RBCs both intra- and 
postoperatively (Figure 5).
Hemoglobin concentration was 107±18 
g/l before and 117±14 g/l aft er the transfusion 
of RBC. Th romboplastin time (P-TT, %) was 
63±16 before and 82±39 aft er transfusion of 
FFP, and platelet count was 98±15 109/l before 
and 181±62 109/l aft er transfusion of platelets. 
Individual hemoglobin concentration, platelet 
count, or P-TT was outside the normal 
laboratory reference range in 38.6% of these 
patients preoperatively and in 29.2% of those 
who had intraoperative RBCT. Among the 70 
patients who received blood products, 7 were 
on acetylsalicylic acid, 3 on warfarin, and one 
on clopidogrel prior to the surgery.
Twenty-six of 37 patients who received 
RBCs during surgery had suff ered from 
intraoperative rupture of an aneurysm.
Total volume of RBC, FFP, and platelet 
concentrates transfused were 730±503 ml, 
560±283 ml, and 500±199 ml, respectively. 
One patient with a large (diameter 20 mm, 
base 8 mm) ruptured basilar aneurysm 
suff ered from a massive bleeding of 10520 
ml during surgery and received 2400 ml of 
RBCs, 800 ml of platelets, and 1000 ml of FFP 
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intraoperatively. Mean blood loss for patients 
who received RBCT during surgery was 1470 
(±1890) ml.
5.2  Intraopera? ve RBCT, risk 
factors, and outcome
When divided into two groups, indexed by 
the need for intraoperative RBCT (yes or no), 
preoperative hemoglobin concentration was 
lower in patients who received intraoperative 
RBCT. A signifi cant diff erence was also found 
in preoperative WFNS and Fisher grades 
between the two groups. Additionally, GOS at 
three months was lower among patients who 
received RBCs during surgery (Figure 5). No 
statistical diff erence was present in aneurysm 
location between the two groups (Table 2). 
In multivariate analysis, intraoperative 
rupture of an aneurysm, lower preoperative 
hemoglobin value, and worse WFNS grade 
independently increased the likelihood of 
intraoperative RBCT (OR 10.86; CI 4.74-
24.89, 0.98; 0.93-0.96, and 1.81; 0.91-1.53, 
respectively). Th e risk for unfavorable 
outcome was signifi cantly increased with 
patients who received RBCs during surgery 
(OR 5.13; CI 1.53-17.15). Other independent 
factors associated with worse neurological 
outcome were worse preoperative WFNS 
grade, worse Fisher grade, and older age 
(1.97; 1.64-2.36, 1.89; 1.23-2.92, and 1.07; 
1.04-1.10, respectively). Th ese fi ndings 
remained essentially unchanged aft er 
including a propensity score of intraoperative 
RBC transfusion in the outcome model.
5.3  Adenosine
Twelve of 825 patients (1.5%) at Helsinki 
University Hospital and 4 of 189 patients 
(2.1%) at Turku University Hospital, thus 
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Figure 5 Flow chart of intraoperative transfusion rates of blood products and patient characteristics 
when divided according to the intraoperative red blood cell transfusion.
Data are presented as numbers of patients (percentage) or mean (±SD), P-value < 0.05 considered signifi gant 
WFNS=World Federation of Neurological Surgeons, GOS=Glasgow outcome scale
488 patients operated on for ruptured cerebral arterial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No perioperative blood 
product transfusions 
n=418 
Preoperatively: 
RBC 5/488 (1.0%) 
FFP 5 (1.0%) 
Platelets 1 (0.2%) 
Postoperatively: 
RBC 17/488 (3.5%) 
FFP 8 (1.6%) 
Platelets 4 (0.9%) 
Intraoperative RBC transfusion (RBCT) 
70 patients who received 
RBC, FFP or platelets 
perioperatively 
Intraoperatively: 
RBC 37/488 (7.6%) 
FFP 15 (3.1%) 
Platelets 6 (1.2) 
RBCT during surgery: 
yes n=37
RBCT during surgery: 
no n=451
P
Female 28 (9.4%) 269 (90.6%)
Male 9 (4.7%) 182 (95.3%) 0.55
Age (years) 56(±13) 54(±12) 0.44
Hemoglobin (g/l) 117(±16) 128(±18) 0.001
Th romboplastin time P-TT% 97(±23) 92(±29) 0.30
Th rombocyte count (109/l) 233(±79) 226(±61) 0.52
WFNS (1-5) 2 (1-5) 4 (1-5) <0.001
WFNS 1 6 (16.2%) 211 (46.8%)
WFNS 2 2 (5.4%) 51 (11.3%)
WFNS 3 1 (2.7%) 19 (4.2%)
WFNS 4 14 (37.8%) 73 (16.2%)
WFNS 5 14 (37.8%) 97 (21.5%)
Fisher grade (1-4) 4(2-4) 4(1-4) 0.005
Fisher grade 1 0 15 (3.3%)
Fisher grade 2 1 (2.7%) 61(13.5%)
Fisher grade 3 6 (16.2%) 140 (31.0%)
Fisher grade 4 30 (81.1%) 222 (49.2%)
Fisher grade not available 0 13 (2.9%)
GOS at 3 months 3(1-5) 4(1-5) <0.001
Intraoperative aneurysm rupture 28 (75.7%) 103 (22.8%) <0.001
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16 of altogether 1014 patients (1.6%), who 
underwent surgery for cerebral arterial 
aneurysm received adenosine during the 
operation (Study II). All but one adenosine 
administration was related to intraoperative 
rupture of an aneurysm. Median single 
dose for adenosine was 12 (range 6-18) mg, 
and when multiple boluses of adenosine 
were required the median cumulative 
dose was 27 (18-89) mg. Aft er 10 min of 
adenosine administration, patients had 
stable hemodynamics.  Mean systolic and 
diastolic blood pressure was 113 ± 14 and 
57 ± 9 mmHg, respectively, and mean heart 
rate  74 ± 15 per minute. Th e distribution 
of aneurysm locations of patients receiving 
adenosine is shown in Table 2.
5.4  Coagula? on during 
replacement of blood loss with 
FFP and RBCs
Intraoperative blood loss and fl uid 
replacement for the two patients are shown 
in Table 3. While coagulation time (CT), 
clot formation time (CFT), alpha angle, and 
maximum clot fi rmness (MCF) were within 
normal reference ranges (ExTEM® and 
InTEM® analysis) before surgery, both patients 
had increased fi brin MCF preoperatively 
(FibTEM®). CFT was prolonged and MCF 
decreased in all samples taken aft er the 
beginning of surgery, but all values remained 
within normal reference ranges. Th e decrease 
in MCF in FibTEM® analysis was more 
Table 2 Aneurysm location in Studies I and II.
Study I II*
Aneurysm location Adenosine RBCT during surgery: yes RBCT during surgery: no
ICA 2 (12.5%) 7 (18.9%) 84 (18.6%)
MCA 4 (25%) 16 (43.2%) 154 (34.1%)
AComm+A1 3 (18.75%) 5 (13.5%) 138 (30.6%)
Pericallosal artery 1 (6.25%) 0 24 (5.3%)
VA 0 1 (2.7%) 2 (0.4%)
PICA 0 3 (8.1%) 21 (4.7%)
PCA 1 (6.25%) 0 3 (0.7%)
Basilar artery 5 (31.25%) 5 (13.5%) 25 (15.5%)
Data are presented as number of patients (percentage). *P=0.06 (aneurysm location between study groups) 
AComm+A1=Anterior communicating artery + Anterior cerebral artery, part A1, ICA=Internal carotid artery 
MCA=Middle cerebral artery, PICA=Posterior inferior cerebellar artery, PCA= Posterior cerebral artery, RBCT= 
red blood cell transfusion, VA=Vertebral artery
Table 3 Patient characteristics and fl uid administration in Study III.
Patient 1 Patient 2
Age (months) 10 5 
Height (cm)/Weight (kg) 78/9.9 67/7.0 
Blood loss, ml 750 380
Total amount of fl uids (ml) 1504 870
Total amount of fresh frozen plasma (ml) 400 240
Total amount of red blood cells (ml) 500 (OR)/60 (ICU) 250 (OR)/60 (ICU)
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profound in Patient 2 than in Patient 1 and 
reached the critical value of 8 mm at the end 
of surgery (Figure 6).
RoTEM® analyses on the fi rst 
postoperative morning were comparable with 
5.5  Coagula? on in vitro
Mannitol in 10 vol% and 20 vol% dilutions 
impairs coagulation more than equiosmolar 
2.5% NaCl in vitro. Th is is refl ected in the 
weaker maximum clot fi rmness (MCF) in 
FibTEM® analysis in the mannitol group than 
in the 2.5% NaCl group aft er both dilutions. 
Additionally, ExTEM® analysis revealed 
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ExTEM® CFT and FibTEM® MCF 
Patient 1 FibTEM® MCF
Patient 2 FibTEM® MCF
Patient 1 ExTEM® CFT
Patient 2 ExTEM® CFT
Figure 6 Results of ExTEM® and FibTEM® analyses in Study III. 
CFT=clot formation time, normal reference range 34–159 s, MCF=maximum clot fi rmness, normal 
reference range 9-25 mm
Mm=millimeters, S=seconds
weaker MCF and longer clot formation time 
(CFT) in the mannitol group than in the 2.5% 
NaCl group aft er 20 vol% dilution. Overall, 
the coagulation profi le of mannitol was more 
disturbed than that of other study solutions. 
An increment in the concentration of the 
NaCl solution resulted in a weaker clot (Table 
4).
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the preoperative values. MCF in FibTEM® 
was increased in both patients, i.e., showing a 
trend towards hypercoagulopathy. Maximum 
lyses (ML) were within normal reference 
ranges in both patients.
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Table 4 RoTEM® results aft er 10 vol% and 20 vol% dilutions with study solutions and the control 
without dilution.
Mannitol 0.9% HS 2.5% HS 3.5% HS P* Control
ExTEM® 
CT
10%
20%
87.6(14.5)1,3
89.8(22.9)3
63.1(15.4)
77.2(33.0)
73.7(25.6)
56.0(7.9)
76.8(47.9)
84.8(44.9)
0.30
0.20
58.7(9.8)
ExTEM® 
CFT
10%
20%
172.5(103.3)
341.4(241.6)2,3
123.4(86.1)
134.0(89.6)
137.4(82.1)
167.2(94.9)1
129.2(62.0)
216.9(97.8)3
0.03
<0.001
119.6(59.7)
ExTEM® 
MCF
10%
20%
49.0(7.9)3
42.3(7.9)2,3 
47.3(6.4)3
51.2(6.5)
50.7(7.6)3
48.2(6.4)3
49.3(5.5)3
47.8(6.9)3
0.36
<0.001
54.8(8.3)
ExTEM® 
Alpha
10%
20%
62.2(10.1)3
44.0(13.8)2,3 
67.5(10.3)
65.5(10.3)
65.4(10.0)
61.8(10.4)3
66.5(7.9)
57.3(8.5)3
0.005
<0.001
67.9(8.6)
FibTEM®  
CT
10%
20%
86.6(20.1)
171.9(197.3)
58.9(11.7)3
75.4(15.0)
64.7(16.2)
63.8(30.2)
84.6(89.1)
83.5(31.0)
0.43
0.09
69.1(21.0)
FibTEM® 
MCF
10%
20%
10.2(3.0)
6.8(2.5)2,3
11.8(3.0)
9.6(3.0)
12.3(4.1)
11.5(3.3)
10.6(3.3)
10.8(2.9)
0.01
<0.001
13.6(6.0)
Values are mean (SD); analyzed by repeated measures ANOVA, *P = overall value between study 
solutions excluding control. 
Comparison of each dilution group with Tukey-Kramer’s post-hoc test. Combinations with p<0.05: 
1Mannintol compared with 0.9% HS, 2 Mannitol compared with 0.9% HS, 2.5% HS, and 3.5% HS 
3Compared with control p<0.05 (t-test).
CT=clotting time, CFT=clot formation time, MCF=maximum clot fi rmness
5.6  Blood pressure and PaCO2-
EtCO2 di? erence
Th e percentage change in MAP had a positive 
correlation between measured PaCO2-
EtCO2 diff erences aft er anesthesia induction 
in a heterogeneous craniotomy patient 
population. Th e greater the percentage 
change in MAP, the greater the PaCO2-
EtCO2 diff erence (p=0.0008, r=0.388). Th e 
time period from intubation to head pinning 
lasted 12.2 (5.6) min. Th e duration of the 
study period did not correlate with PaCO2-
EtCO2 diff erence.
Patients were subgrouped aft er study 
completion according to the diff erence 
between MAP awake and MAP during 
PaCO2 determination into four groups: MAP 
decrease of   <20% (n=17), 20-29% (n=24), 
30-35% (n=16), and >35% (n=15). PaCO2 was 
higher and PaCO2-EtCO2 diff erence greater 
in patients with MAP decrease of over 35% or 
30-35% than in patients with MAP decrease 
of less than 20%: 0.96 (0.43) kPa or 0.85 
(0.31) kPa versus 0.55 (0.24) kPa, respectively 
(p<0.05 between groups). 
Increase in fraction of inspired oxygen 
(FiO2) correlated negatively with PaCO2-
EtCO2 diff erence (p=0.01). No correlation 
between decrease in MAP and change in 
PaO2/FiO2 ratio (P/F) was found.
5.7  Prone versus si?  ng posi? on
Data from 58 patients (30 in prone position, 
28 in sitting position) were analyzed aft er the 
assessment of the eligibility of 72 patients. 
Exclusion fl ow charts have been reported in 
conjunction with the original reports of both 
individual studies [10,85].
When combined data were divided in 
two groups according to the study fl uid (RAC 
vs. HES), patients in the RAC group had 
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higher weight, height, and body surface area 
(BSA). Cumulative mean dose of basal RAC 
was similar between the study groups. When 
divided according to the surgery position, 
the groups were comparable, with the 
exception that patients in the sitting position 
were younger (p<0.01) and had higher ASA 
classifi cation (p<0.001). 
A signifi cant diff erence emerged 
between mean cumulative doses of RAC and 
HES (prone and sitting positions combined) 
in optimizing the fl uid fi lling at 30 min 
and at the end of surgery (452±155 ml vs. 
341±109 ml and 678±390 ml vs. 455±253 
ml, respectively). Aft er adjusting RAC and 
HES doses according to patients’ weight, the 
mean doses of RAC at 30 min and at the end 
of surgery remained higher than those of 
HES (5.5±1.6 ml/kg vs. 4.8±1.7 and 8.2±4.2 
ml/kg vs. 6.4±3.6 ml/kg, respectively), but 
statistical signifi cance was lost. Th ere was 
no diff erence between RAC and HES doses 
before positioning in either position. Six 
patients receiving RAC (2 in sitting and 4 in 
prone position) and one patient receiving 
HES (prone position) were considered non-
responders.
Patients in the sitting position had lower 
MAP over time and higher CI and SVI than 
patients in the prone position. No diff erence 
was present in study fl uid consumption 
between the two groups during surgery.
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6.1  Transfusion of RBC, FFP, and 
platelets and risk factors 
associated with RBCT
Th e rate of intraoperative RBCT in our 
material of 488 patients was 7.6%. Previously 
reported intraoperative transfusion rates 
of RBCs in ruptured cerebral aneurysm 
surgery populations have varied between 
5.6% and 27.2%. In a study conducted by 
Coutere and coworkers, the transfusion rate 
was 5.6%. Th is study consisted of a larger 
entity of cerebrovascular surgery patients, 
including those with ruptured (n=77) and 
unruptured aneurysms, arteriovenous 
malformations, and carotid artery stenosis 
[132]. Two other larger studies of 441 and 101 
(of which 5 had aneurysm coiled) patients 
have reported signifi cantly higher incidences 
(27.2% and 19.8%, respectively) of RBCT 
[131,133]. Intraoperative thrombocyte 
and FFP transfusion rates, 1.2% and 3.6%, 
respectively, can be considered low, although 
no comparative data exist.
In aneurysm surgery, a stable surgery 
can abruptly turn into a catastrophic situation 
due to the rupture of an aneurysm. In these 
situations, anesthesiologists are likely to give 
RBCT preemptively to prevent the situation 
from escalating further. Th is conclusion can 
be drawn from our results, where 68% of the 
intraoperative RBCTs were administered aft er 
a rupture of an aneurysm. Moreover, when 
identifying variables that might predict risk of 
intraoperative RBCT, intraoperative rupture 
of an aneurysm independently increased the 
risk of intraoperative RBCT. Higher Fisher 
grade and lower preoperative hemoglobin 
value emerged from multivariate analysis as 
independent risk factors for intraoperative 
RBCT, suggesting that, overall, patients 
needing RBCT are those who are more 
seriously ill before surgery.
6.  DISCUSSION 
Patients who had intraoperative RBCT 
were in worse neurological condition three 
months aft er surgery. Th is fi nding is in line 
with earlier reports indicating that RBCT is 
associated with increased risk of vasospasm 
and worse neurological outcome [123,180]. 
Although intraoperative RBCT in our study 
increased patient’s risk for worse neurological 
outcome, even when controlled with other 
variables, such as intraoperative rupture of an 
aneurysm, WFNS grade, and Fisher grade, it 
is debatable whether a true relationship exists 
between intraoperative RBCT and patient 
outcome. RBCT may only refl ect the severity 
of the disease, especially as in our material 
the frequency of intraoperative rupture of an 
aneurysm among patients receiving RBCT 
was relatively high. On the other hand, high 
OR for intraoperative RBCT in outcome 
analysis remained even when propensity 
score for RBCT was added to the analysis. 
Th is suggests that in our material there is 
a true relation between RBCT and worse 
neurological outcome. For our patients, 
the age of transfused RBCs was not known, 
but according to recent fi ndings, the age of 
RBCs does not aff ect patient’s outcome or 
development of organ dysfunction [181,182].
6.2  Adenosine 
In the event of sudden intraoperative 
rupture of an aneurysm, adenosine-induced 
cardioplegia is a relatively novel method to 
stop the bleeding, thus facilitating temporary 
clipping of an aneurysm. Aft er a few single 
patient case studies of adenosine-induced 
transient asystole in cerebral arterial 
aneurysm surgery, we were the fi rst to 
describe a series of patients who had received 
adenosine for this indication intraoperatively 
aft er identifying 16 patients of 1014 
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operated on for cerebral arterial aneurysm 
[17,183,184].  Th e median single dose of 
adenosine in our study was 12 mg, in line with 
the recommended dose for supraventricular 
tachycardia [185,186]. Subsequently, 
adenosine dose to achieve asystole in our 
clinic has increased according to the dose 
recommendation of 0.2-0.4 mg per ideal body 
weight of Bebawy and coworkers [147]. With 
that dosing, a profound hypotension (systolic 
blood pressure < 60 mmHg) was achieved 
for a period of 45 seconds and duration of 
hypotension had a positive correlation with 
adenosine dosing. Bebawy and coworkers 
reported an in-depth analysis of adenosine 
use (using partly the same patients as in 
the previous publications) and concluded 
that short-term morbidity associated with 
adenosine use is minimal [187]. 
Adenosine is now considered a useful 
tool in aneurysm surgery, not only when 
bleeding occurs from ruptured aneurysm 
and visibility is lost, but also in situations 
where temporary clipping of a feeding artery 
is not feasible. Historically, these patients 
have been treated with extracranial artery 
occlusion, hypotensive anesthesia, and even 
hypothermic circulatory fl ow arrest [188]. 
As intraoperative asystole is not an offi  cial 
indication of adenosine, some concerns of its 
safety have been raised. In our retrospective 
review, patients had stable hemodynamics 
10 minutes aft er administration of 
adenosine, and no adverse eff ects were 
reported. Furthermore, three relatively 
large retrospective reviews concluded that 
use of adenosine in intracranial aneurysm 
surgery is not associated with worse 
neurological outcome or increased cardiac 
complications or mortality [189-191]. 
Prospective randomized trials would provide 
more information about the safety profi le of 
adenosine in aneurysm surgery. 
6.3  Blood coagula? on – e? ect of 
mannitol, HS, and FFP 
In an in vitro environment, 15% mannitol 
solution decreases blood coagulation 
more than equimolar and equivolemic 
2.5% hypertonic saline solution. In 
thromboelastometry tracing, not only is the 
coagulation process slower, but the forming 
clot is weaker. Impairment in FibTEM® 
analysis suggests that the weaker clot is, at 
least partly, the result of fi brin defi ciency. 
An increment in HS concentration may 
also increase coagulation impairment, so it 
remains speculative how HS, with a higher 
concentration and a lower volume, compares 
with 15% mannitol. Historically, mannitol has 
been the primary solution in osmotherapy 
to decrease elevated intracranial pressure 
(ICP), but HS has gained popularity as an 
alternative method. HS seems to be equally if 
not more eff ective in reducing ICP and is also 
associated with less severe side-eff ects.
In our case report of two pediatric 
neurosurgical patients, we could see that 
by applying early transfusion of FFP the 
coagulation capacity remained almost normal 
throughout the surgery even when patients 
suff ered from massive bleeding. Noteworthy 
is that even with FFP early infusion a marked 
decrease in PT% was evident (25-29% during 
surgery). More notably, the fi brinogen-
dependent clot weakened, reaching abnormal 
levels. One of the patients received tranexamic 
acid during surgery. Administration of 
tranexamic acid has been reported to 
decrease need for blood product transfusion 
in pediatric craniofacial surgery [192]. 
However, a relatively large amount of colloids 
was then needed for fl uid replacement, 
which is a questionable solution with today’s 
knowledge of the harms associated with 
colloid use. A recent review addressing 
perioperative transfusion of blood products 
with pediatric patients during craniotomy 
recommends a fairly restricted use of blood 
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products due to their possible side-eff ects, 
but at the same time acknowledges the great 
challenge of fi nding an optimal transfusion 
regimen when abrupt sudden bleeding 
occurs. Th romboelastometry is off ered as 
one solution to guide maintenance of normal 
coagulation capacity [193]. 
Th e avoidance of perioperative 
bleeding and postoperative hematomas in 
neurosurgery is essential to prevent worse 
outcome. Patients with a brain tumor oft en 
have various coagulation abnormalities, 
posing a challenge for perioperative treatment 
of these patients [4,194]. Both patients 
in our report were in a hypercoagulable 
state prior to surgery. Had the coagulation 
capacity been normal before operation, the 
fi brinogen-dependent clot weakness would 
probably have been more profound even 
with early transfusion of FFP. Both patients 
received also mannitol at the beginning of 
surgery, potentially interfering with blood 
coagulation. Close monitoring of coagulation 
status postoperatively is important to detect 
possible hypercoagulability and increased risk 
of thrombosis. 
Our results, which should be verifi ed 
in vivo, indicate that from the viewpoint of 
blood coagulation HS might be less harmful 
than mannitol in treatment of elevated 
ICP. Especially in situations where the 
neurosurgical patient suff ers from massive 
bleeding, mannitol should be avoided and 
early infusion of FFP should be considered to 
maintain the required coagulation capacity. It 
must be noted, however, that effi  cacy of FFP 
to correct a fi brinogen defi cit is limited.
Th romboelastometry (RoTEM®) off ers a 
more dynamic evaluation of the coagulation 
process compared with traditional laboratory 
tests and was used in our studies to evaluate 
coagulation disturbance caused by bleeding 
and dilution. Th romboelastometry is a well-
established method in coagulation analysis 
of patients suff ering from bleeding [161]. 
Th romboelastometry may, however, lack 
consistency in results from the same sample 
if diff erent analyzers are used. MCF value 
shows the highest consistency [195]. 
6.4  Impact of change in MAP on 
PaCO2-EtCO2 di? erence 
Th e noted signifi cant positive correlation 
between the MAP decrease and the EtCO2-
PaCO2 diff erence immediately aft er 
induction of anesthesia in this heterogeneous 
craniotomy patient population indicates that 
monitoring of EtCO2 as an estimate of PaCO2 
is misleading and optimal ventilation should 
be confi rmed by arterial blood gas analysis 
in patients undergoing neurosurgery. Th is is 
essential because in neurosurgical patients 
with an occupying intracranial lesion any 
increase in CBF due to elevated PaCO2 
may result in a sudden increase in ICP. 
In hypotension, carbon dioxide reactivity 
becomes impaired, and the combined eff ect 
on CBF is even more profound [25,26]. 
Reliability of EtCO2 as an estimate 
of PaCO2 has been questioned before and 
our results are in line with earlier reports. 
Although we showed a linear correlation 
between MAP change and EtCO2-PaCO2 
diff erence, confl icting data exist, especially 
when evaluating diff erent surgery positions 
[47,48,196]. Th is diminishes the usefulness of 
EtCO2 measurement as a surrogate marker of 
PaCO2 and supports the direct measurement 
of PaCO2. When patients in our study were 
divided into groups according to the decrease 
in MAP aft er induction (decrease of   <20%, 
20-29%, 30-35%, and > 35%), EtCO2 remained 
similar, but PaCO2-EtCO2 was greater in 
patients with a MAP decrease of over 30% 
than in patients with a MAP decrease of less 
than 20%. Additionally, minute ventilation 
values were slightly lower (although not 
statistically signifi cant) when MAP decreased 
over 30%. Th is perhaps indicates that 
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adjustment of mechanical ventilation was 
guided exclusively by the EtCO2 value. In 
fact, the patients were similarly ventilated 
according to the EtCO2 in the study groups, 
even though PaCO2 was increased in patients 
with a pronounced decrease in MAP.
An increment of FiO2 has been reported 
to marginally increase the EtCO2-PaCO2 
diff erence [197]. Our results show the 
opposite, as we found a negative correlation 
between FiO2 and EtCO2-PaCO2 diff erence. 
Moreover, 100% inspired oxygen leads to 
the formation of atelectasis and increases 
intrapulmonary shunt, but its eff ect on EtCO2-
PaCO2 is unknown [50,198]. We observed 
no correlation between P/F ratio change 
and MAP decrease. Th is may indicate that 
MAP aff ects EtCO2-PaCO2 independently of 
atelectasis. 
6.5  Hemodynamics in prone and 
si?  ng posi? ons 
Goal-directed fl uid administration to achieve 
stable hemodynamics did not diff er between 
surgery in sitting and prone positions. HES 
was more eff ective than RAC in achieving 
comparable hemodynamics, as according 
to our results, requirement of RAC was 
1.5-fold that of HES. Clinically, this might 
be an overestimation, because when fl uid 
doses were adjusted with patients’ weight, a 
diff erence between HES and RAC doses was 
maintained (1:1.3), but signifi cance was lost. 
Th is fi nding supports other recent reports 
suggesting that the ratio between colloids and 
crystalloids is more equal than earlier thought 
[9,10,85,199]. Th e clinical evaluation revealed 
that patients in our study were normovolemic 
prior to surgery. With hypovolemic patients, 
volume-expanding capabilities of HES and 
RAC might be diff erent.
According to our results, the previously 
reported decrease in cardiac function 
[176,177,200] in the prone position can 
be prevented with stroke volume-directed 
fl uid administration and moderate use of 
vasoactive drugs. Moreover, we demonstrated 
that with similar fl uid administration, 
patients in the sitting position maintained 
good cardiac function aft er positioning 
and a decrease in cardiac function did not 
occur [173]. Although MAP remained 
adequate throughout the surgery, it was 
lower in the sitting position, confi rming 
a tendency towards hypotension in this 
position. Patients in the sitting position in 
our study wore antigravity suits, which in part 
prevents pooling of the blood to the lower 
extremities, thus helping to stabilize patient 
hemodynamics. 
No universally accepted method of 
measuring CPP in neurosurgical patients 
exists. Th e standard in our department during 
craniotomy is to measure the MAP at the 
level of the foramen Monroi, giving us a more 
accurate estimate of CPP. When measuring 
MAP at the level of the heart, the values are 
15-25 mmHg higher, better refl ecting the 
systemic blood pressure [201,202]. 
Th e Vigileo Flotrac System (version 
3.02) was used in Study VI for cardiac output 
monitoring, following the normal practice of 
our department when perioperative cardiac 
output monitoring is required. Th e studies 
done with older versions of Vigileo have 
shown an underestimation of CO in a low 
vascular resistance state compared with the 
intermittent bolus thermodilution technique 
[203,204]. Compared with the previous 
versions, the newer third-generation system 
has shown an improvement, with accuracy 
even in the low vascular resistance state, e.g. 
in septic shock [205,206]. Acute changes 
in peripheral vascular resistance caused 
by vasopressor may, however, reduce the 
reliability of CO measurement [207,208]. 
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Th is thesis aimed to examine critical aspects 
of neuroanesthesia with regard to CBF, CPP, 
blood coagulation, and transfusion of blood 
products.
In our material, transfusion frequencies 
of RBCs, FFP, and platelets during ruptured 
cerebral aneurysm surgery were low. 
Intraoperative RBCT seems to be preemptive 
in nature according to the hemoglobin 
levels prior to transfusion. RBCT is strongly 
associated with intraoperative rupture of an 
aneurysm. Lower hemoglobin value, larger 
aneurysm size, and more severe bleeding 
(higher Fisher grade) also increased the 
likelihood of intraoperative RBCT.
Intraoperative RBCT may itself worsen 
SAH patients’ neurological outcome, even 
when controlled with other variables such 
as WFNS grade, Fisher grade, and patients’ 
age. In the event that sudden intraoperative 
rupture of an aneurysm occurs, adenosine-
induced transient asystole can be used to 
stop the bleeding and facilitate clipping of 
the aneurysm without compromising patient 
hemodynamics aft erwards.
During a massive bleeding early infusion 
of FFP together with RBCT should be 
considered to preserve the normal coagulation 
capacity required for neurosurgery. Based on 
our in vitro observation, HS might be more 
favorable solution than mannitol due to its 
less harmful eff ect on blood coagulation. An 
increment in HS concentration may have a 
negative eff ect on coagulation.
Reliability of EtCO2 as an estimate 
of PaCO2 aft er anesthesia induction is not 
adequate, as seen in the correlation between 
a decrease in MAP and EtCO2-PaCO2 
diff erence. Optimal ventilation aft er induction 
of anesthesia should be confi rmed by arterial 
blood gas analysis in patients undergoing 
neurosurgery to prevent a potentially harmful 
increase in PaCO2, and consequently, in CBF. 
Anesthesia in both sitting and prone 
positions is associated with changes in blood 
pressure and cardiac function. However, 
preemptive GDT with either RAC or HES 
solutions before positioning enables a stable 
hemodynamic state during neurosurgery in 
both positions. Th e fl uid requirement was 
not diff erent between the two positions, and 
the ratio between HES and RAC to achieve 
comparable hemodynamics was 1:1.5.
7.  CONCLUSIONS
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Clinical Implications and Suggestions for Further Studies
With modern microsurgical techniques 
and well-executed neuroanesthesia, the 
requirement of intraoperative blood product 
transfusion is low during surgery for 
ruptured arterial aneurysm. By preventing 
intraoperative rupture of an aneurysm with 
good hemodynamic control, the need for 
potentially harmful RBCT is less probable. 
Adenosine-induced transient asystole is a 
feasible method, without compromising 
hemodynamics, in the occurrence of 
intraoperative rupture of an aneurysm. 
Th is enables the neurosurgeon to clear the 
surgical fi eld, facilitating temporary clipping 
to stop the bleeding in this potentially life-
threatening situation.
Early infusion of FFB should be 
considered instead of crystalloids in 
replacement therapy of marked bleeding to 
preserve normal coagulation capacity. Th e 
less harmful eff ect of HS, relative to mannitol, 
on blood coagulation may shift  the decision 
towards HS when choosing an optimal 
solution for treatment of elevated ICP or 
brain swelling, at least when excess bleeding 
occurs. However, the clinical relevance of this 
fi nding remains unclear and warrants further 
study. 
Neurosurgical patients with an 
intracranial volume-occupying lesion are 
extremely vulnerable to changes in CBF. 
As PaCO2 is a strong regulator of CBF, an 
uncontrolled increase in PaCO2 should be 
avoided at all times. Reliability of EtCO2 as an 
8.  CLINICAL IMPLICATIONS AND SUGGESTIONS FOR 
FURTHER STUDIES
estimate of PaCO2 aft er anesthesia induction 
is inadequate. Th e eff ect that a possible 
decrease in arterial blood pressure can have 
on PaCO2 should be noted, and ventilation 
ought to be confi rmed by arterial blood gas 
analysis.
Preemptive GDT with either RAC or HES 
solutions before positioning enables a stable 
hemodynamic state during neurosurgery 
in both sitting and prone positions. Th e 
fl uid requirement did not diff er between the 
two positions. Slightly less HES is needed 
to achieve comparable hemodynamics, but 
is it questionable whether this advantage 
outweighs the recent concerns regarding 
colloid safety.  Stable hemodynamics prevents 
misleading fl uctuation in EtCO2, allowing 
early detection of VAE should it occur when 
the patient is operated on in a sitting position.
Optimal fl uid administration and 
transfusion practice of blood products with 
neurosurgical patients remain unknown 
despite the increasing number of studies 
conducted. Whether colloids have a place 
in fl uid administration in the future in 
neurosurgical patient populations remains 
speculative, warranting further research.
Debate regarding the optimal 
hemoglobin level for neurosurgical patients, 
particularly SAH patients, is ongoing. 
Prospective controlled randomized studies 
are needed to clarify the associations between 
RBCT, anemia, and outcome.
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Transfusion Frequency of Red Blood Cells, Fresh Frozen Plasma, and Platelets During
Ruptured Cerebral Aneurysm Surgery
Teemu Luostarinen1, Hanna Lehto3, Markus B. Skrifvars2, Riku Kivisaari3, Mika Niemela¨3, Juha Hernesniemi3,
Tarja Randell1, Tomi Niemi1
-BACKGROUND: The use of blood products after sub-
arachnoid hemorrhage (SAH) is common, but not without
controversy. The optimal hemoglobin level in patients with
SAH is unknown, and data on perioperative need for red
blood cell (RBC), fresh frozen plasma (FFP), or platelet
transfusions are limited. We studied perioperative admin-
istration of RBCs, FFP, and platelets and the impact of red
blood cell transfusions (RBCTs) on outcome in patients un-
dergoing surgery for ruptured a cerebral arterial aneurysm.
-METHODS: A retrospective analysis was performed of
488 patients with aneurysmal SAH during the years
2006e2009 at Helsinki University Central Hospital. Patients
who received RBC, FFP, or platelet concentrates perioper-
atively were compared with a cohort of patients from the
Helsinki database of aneurysmal SAH who did not receive
transfusions. A multiple regression model was created to
identify factors related to transfusion and outcome.
-RESULTS: RBC, FFP, or platelet concentrates were given
in 7.6% (37 of 488), 3.1% (15 of 488), and 1.2% (6 of 488) of
patients intraoperatively and in 3.5% (17 of 486), 1.6% (8 of 488),
and 0.9% (4 of 488) of patients postoperatively. Of 37 intra-
operative RBCTs, 26 were related to intraoperative rupture of
the aneurysm. Intraoperative RBCTs were associated with
lower preoperative hemoglobin concentration, higher World
Federation of Neurosurgical Societies classification, and
intraoperative rupture of an aneurysm. In multivariate
analysis, intraoperative RBCT (odds ratio [ 5.13, 95%
confidence interval[ 1.53e17.15),worseWorld Federation of
Neurosurgical Societies classification and Fisher grade (odds
ratio [ 1.97, confidence interval [ 1.64e2.36 and odds
ratio[ 1.89, confidence interval[ 1.23e2.92, respectively),
and increasing age (odds ratio[ 1.07, confidence interval[
1.04e1.10) independently increased the risk of poor neuro-
logic outcome at 3 months.
-CONCLUSIONS: Transfusion frequencies of RBCs, FFP,
and platelets were relatively low. Intraoperative RBCT was
strongly related to intraoperative rupture of the aneurysm
in patients with poor-grade SAH. The observed association
between poor outcome and RBCT in patients with SAH
warrants further study.
INTRODUCTION
While the debate of optimal hemoglobin level for apatient with subarachnoid hemorrhage (SAH) isongoing, the transfusion rate of red blood cells
(RBCs), fresh frozen plasma (FFP), or platelets during surgery for
ruptured aneurysm and factors correlating with it has received less
attention (4-6, 10, 14). Earlier reports indicated that the frequency
of intraoperative red blood cell transfusion (RBCT) was 5.6%e
27.2% (2, 7, 8), but the incidence of intraoperative transfusion of
FFP or platelets is unknown. The present study was designed to
describe blood product use and associated clinical characteristics
in patients operated on for ruptured cerebral arterial aneurysm at
Helsinki University Central Hospital, Helsinki, Finland, between
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January 2006 and September 2009. The hypothesis was that the
need for RBCT in our clinic is low, and FFP and platelet trans-
fusions are used mainly in patients on long-term anticoagulation
or antiplatelet therapy.
MATERIALS AND METHODS
After approval of Helsinki University Central Hospital Scientiﬁc
Board, we identiﬁed patients who had undergone surgery for
ruptured cerebral arterial aneurysm between January 2006 and
September 2009 from the Helsinki aneurysm registry and retrieved
demographics of these patients. We collected surgical and intensive
care unit data and identiﬁed patients who had received RBCs, FFP,
or platelets intraoperatively or during the immediate postoperative
period (within 24 hours of surgery). We also included patients who
had been given transfusions during preparation for surgery.
The retrieved variables included age, sex, localization of the
aneurysm, preoperative Glasgow Coma Scale score 3e15, World
Federation of Neurological Surgeons (WFNS) classiﬁcation 1e5,
Fisher grade 1e4, occurrence of intraoperative rupture of an
aneurysm, comorbidities, medication, preoperative laboratory re-
sults, hemoglobin concentration, platelet count and plasma pro-
thrombin time value (P-PT, %) before and after transfusion, the
amount of transfused blood products, and blood loss. Glasgow
Outcome Scale (GOS) score 1e5 at 3 months was used to evaluate
outcome. In the logistic regression analysis, the GOS score was
dichotomized into good outcome (GOS score 4e5) and bad
outcome (GOS score 1e3) and used as the endpoint. We
compared clinical characteristics of patients undergoing surgery
for ruptured cerebral arterial aneurysm based on the need for
transfusion of any type of blood product.
Statistics
Descriptive statistics are shown as mean  (SD) or median
(range). Fisher exact test was used for categorical variables, and
Mann-Whitney U test was used for continuous variables. We used
logistic regression and odds ratios to assess relationships between
the 2 outcome variables and each main study variable. Variables
tested for multivariate analysis of risk factors for RBCT were he-
moglobin concentration, platelet count, P-PT, %, WFNS classiﬁ-
cation, Fisher grade, aneurysm location, intraoperative aneurysm
rupture, aneurysm size, and sex. For outcome analysis, variables
were intraoperative rupture of an aneurysm, RBCT, WFNS clas-
siﬁcation, Fisher grade, age, preoperative hemoglobin, and
aneurysm location. Variables associated with study outcomes with
P < 0.1 in univariate analysis were included in multivariable lo-
gistic regression analysis. A propensity score was calculated using
covariates that were associated with intraoperative RBCT and was
added to multivariate analysis assessing outcome as a covariate.
Additionally, variance inﬂation factor was calculated to detect
possible multicollinearity between the covariates. All statistical
analyses were performed using IBM SPSS Statistics version 21
(IBM Corp., Armonk, New York, USA).
RESULTS
During the study period, 488 patients underwent surgery for a
ruptured cerebral arterial aneurysm. RBC, FFP, or platelet trans-
fusions were given to 70 patients either during surgery or in the
immediate postoperative period. Intraoperative RBC, FFP, and
platelet transfusions were given in 7.6% (37 of 488), 3.1% (15 of
488), and 1.2% (6 of 488) of patients, and postoperative RBC, FFP,
and platelet transfusions were given in 3.5% (17 of 486), 1.6% (8
of 488), and 0.9% (4 of 488) of patients. In 5 patients, RBCs were
transfused intraoperatively and postoperatively (Table 1).
Hemoglobin concentration was 107 g/L  18 before and 117 g/L
 14 after transfusion of RBCs. P-PT, % was 63  16 before and 82
 39 after transfusion of FFP, and platelet count was 98 109/L  15
before and 181 109/L  62 after transfusion of platelets. Among the
70 patients who received blood products, 7 were taking acetylsa-
licylic acid, 3 were taking warfarin, and 1 was taking clopidogrel
before surgery. Hemoglobin concentration, platelet count, and P-
PT, % were outside the normal laboratory reference ranges in
38.6% of transfused patients preoperatively and in 29.2% of pa-
tients with intraoperative RBCT. Tranexamic acid was given to
68.6% of patients on admission to Töölö Hospital before surgery.
Of 37 patients who received RBCs during surgery, 26 had experi-
enced intraoperative rupture of the aneurysm. Similarly, 7 of 15
patients who required intraoperative FFP transfusion and 1 of 6
patients who required platelet transfusion had intraoperative
rupture of the aneurysm.
Total volumes of RBCs, FFP, and platelet concentrates trans-
fused were 730 mL  503, 560 mL  283, and 500 mL  199. One
patient with a large (20 mm diameter, 8 mm base) ruptured basilar
aneurysm experienced a massive bleed of 10,520 mL during sur-
gery and received 2400 mL of RBCs, 800 mL of platelets, and 1000
mL of FFP intraoperatively. Mean blood loss for patients who
received RBCT during surgery was 1470 ( 1890) mL.
Intraoperative RBCT
Table 2 shows main clinical characteristics of the 488 patients
divided into 2 groups based on the need for intraoperative
RBCT (yes or no). Preoperative hemoglobin concentration was
lower in patients who received intraoperative RBCT. There also
was a signiﬁcant difference in preoperative WFNS classiﬁcation
and Fisher grade between the 2 groups. GOS score at 3 months
was lower among patients who received RBCs during surgery.
There was no statistical difference in aneurysm location between
the 2 groups. In multivariate analysis, lower preoperative
hemoglobin value, worse Fisher grade, increase in aneurysm
size, and intraoperative rupture of an aneurysm independently
increased the likelihood of intraoperative RBCT (Table 3).
Table 1. Transfusion Rates of Perioperative Red Blood Cells,
Fresh Frozen Plasma, and Platelets
Before Surgery During Surgery Postoperative Total
RBCs 5/488 (1.0%) 37/488 (7.6%)* 17/488 (3.5%) 52/488
FFP 5 (1.0%) 15 (3.1%)y 8 (1.6%) 23/488
Platelets 1 (0.2%) 6 (1.2%)z 4 (0.9%) 9/488
FFP, fresh frozen plasma; RBCs, red blood cells.
*RBCs also were given before surgery in 3 patients and postoperatively in 4 patients.
yFFP was given before surgery in 4 patients and postoperatively in 1 patient.
zThrombocytes were given before surgery in 1 patient and postoperatively in 1 patient.
WORLD NEUROSURGERY 84 [2]: 446-450, AUGUST 2015 www.WORLDNEUROSURGERY.org 447
ORIGINAL ARTICLE
TEEMU LUOSTARINEN ET AL. BLOOD PRODUCTS IN RUPTURED CEREBRAL ANEURYSM SURGERY
Outcome
The risk for unfavorable outcome was signiﬁcantly increased with
patients who received RBCs during surgery (odds ratio ¼ 5.13,
conﬁdence interval ¼ 1.53e17.15). Other independent factors
associated with worse neurologic outcome were older age and
worse WNFS classiﬁcation and Fisher grade preoperatively. These
ﬁndings remained similar after including a propensity score of
intraoperative RBCT in the outcome model (Table 4).
DISCUSSION
In the present study, we aimed to characterize the incidence of
RBC, FFP, and platelet transfusion, and we found a low rate of
intraoperative transfusions in patients undergoing clipping of a
ruptured cerebral aneurysm. Most RBCTs were related to intra-
operative aneurysm rupture, and FFP and platelet transfusions
were related to the preemptive reversal of anticoagulant or anti-
platelet therapy. We noted an association between RBCT and poor
outcome after 3 months, and this ﬁnding warrants further study.
This observation is clinically important in view of earlier reports of
higher rate of RBCTs during aneurysm surgery (7, 8), which may
inﬂuence patient outcome and treatment costs. Furthermore, it
appears that need for intraoperative RBCT is strongly related to
the sudden rupture of an aneurysm during surgery, although
almost 40% of the patients had coagulation disturbance
preoperatively.
Transfusion of FFP and platelets seemed to be preemptive and
related to patient use of anticoagulant or antiplatelet therapy. FFP
and platelet transfusions were used to correct evident coagulation
disturbances before surgery, such as in patients on long-term
anticoagulation or antiplatelet therapy. Transfusion of platelets
was so scarce in this patient population that it is impossible to
draw deﬁnite conclusions of the reasons behind transfusions.
In 2 other larger studies including 441 and 101 (of which 5 had
aneurysm coiled) patients, respectively, signiﬁcantly higher use
(27.2% and 19.8%, respectively) of RBCs was reported (7, 8). The
low incidence of intraoperative RBCT (7.6%) in our report
including 488 patients undergoing aneurysm surgery is in line
with the incidence of 5.6% reported earlier by Couture et al. (2) in
a series of 77 patients with ruptured aneurysms. However, their
result is part of a larger entity of cerebrovascular surgery cases
(ruptured and unruptured aneurysms, arteriovenous
malformations, and carotid artery stenosis) and the number of
patients with ruptured aneurysm was small (n ¼ 77).
The hemoglobin level before RBCT was not abnormally low
(i.e., hemoglobin concentration was within normal laboratory
reference range). This ﬁnding reﬂects the nature of aneurysm
Table 2. Preoperative Demographic Data Divided into 2 Groups
Based on Need for Intraoperative Red Blood Cell Transfusion
RBCT During
Surgery: Yes
RBCT During
Surgery: No P Value
Female 28 (9.4%) 269 (90.6%)
Male 9 (4.7%) 182 (95.3%) 0.55
Age (years) 56 ( 13) 54 ( 12) 0.44
Hemoglobin (g/L) 117 ( 16) 128 ( 18) 0.001
P-PT, % 97 ( 23) 92 ( 29) 0.30
Thrombocyte count (109/L) 233 ( 79) 226 ( 61) 0.52
WFNS classification 2 (1e5) 4 (1e5) < 0.001
WFNS 1 6 (16.2%) 211 (46.8%)
WFNS 2 2 (5.4%) 51 (11.3%)
WFNS 3 1 (2.7%) 19 (4.2%)
WFNS 4 14 (37.8%) 73 (16.2%)
WFNS 5 14 (37.8%) 97 (21.5%)
Fisher grade 1e4 4 (2e4) 4 (1e4) 0.005
Fisher 1 0 15 (3.3%)
Fisher 2 1 (2.7%) 61 (13.5%)
Fisher 3 6 (16.2%) 140 (31.0%)
Fisher 4 30 (81.1%) 222 (49.2%)
Fisher grade not available 0 13 (2.9%)
GOS score at 3 months 3 (1e5) 4 (1e5) < 0.001
Intraoperative aneurysm
rupture
28 (75.7%) 103 (22.8%) < 0.001
Aneurysm location
ICA 7 (18.9%) 84 (18.6%)
MCA 16 (43.2%) 154 (34.1%)
ACommþA1 5 (13.5%) 138 (30.6%)
Pericallosal artery 0 24 (5.3%)
VA 1 (2.7%) 2 (0.4%)
PICA 3 (8.1%) 21 (4.7%)
PCA 0 3 (0.7%)
Basilar artery 5 (13.5%) 25 (15.5%) 0.06
Values are mean ( SD) and median (range) or number (percentage).
ACommþA1, anterior communicating artery þ anterior cerebral artery, part A1; GOS,
Glasgow Outcome Scale; ICA, internal carotid artery; MCA, middle cerebral artery;
PCA, posterior cerebral artery; PICA, posterior inferior cerebellar artery; P-PT, %,
plasma prothrombin time value; RBCT, red blood cell transfusion; VA, vertebral artery;
WFNS, World Federation of Neurological Surgeons.
Table 3. Multivariable Analysis of Factors Associated with
Increased Risk of Intraoperative Red Blood Cell Transfusion
Preoperative Factor OR 95% CI P Value
Preoperative hemoglobin (increase by 1 g/L) 0.98 0.93e0.96 0.04
WFNS classification (increase) 1.81 0.91e1.53 0.22
Fisher grade (increase) 2.19 1.03e4.70 0.04
Intraoperative aneurysm rupture (yes) 10.86 4.74e24.89 < 0.001
Aneurysm size (increase by 1 mm) 1.07 1.01e1.41 0.03
CI, confidence interval; OR, odds ratio; WFNS, World Federation of Neurological
Surgeons.
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surgery, where a stable surgery can abruptly turn catastrophic
because of the rupture of an aneurysm. In the present study,
intraoperative rupture of an aneurysm was strongly associated with
intraoperative RBCT, and 68% of the transfusions occurred after a
rupture of an aneurysm. Clinicians may be inclined to give RBCT
preemptively. The fact that worse Fisher grade together with lower
preoperative hemoglobin value was shown by multivariate analysis
as an independent risk factor for RBCT suggests that overall pa-
tients who need blood product transfusions are the patients with
more severe SAH.
Intraoperative RBCT was associated with worse neurologic
outcome, even when controlled for other variables, such as
intraoperative rupture of an aneurysm, WFNS classiﬁcation, and
Fisher grade. This ﬁnding must be seen mainly as hypothesis
generating but is in line with ﬁndings by Smith et al. (19), who
reported that intraoperative RBCs increased the incidence of
vasospasm. Whether there is a true relationship between
intraoperative RBCT and patient outcome or whether RBCT
reﬂects only the severity of the disease is uncertain, especially as
in our study the number of intraoperative ruptures of aneurysms
among the patients who received RBCs during surgery was
relatively high. Intraoperative rupture of an aneurysm itself was
not an independent risk factor for worse neurologic outcome in
our analysis; this is probably due to the fact that, in addition to
clinically relevant ruptures, even the slightest bleeding from an
aneurysm sac is considered an intraoperative rupture in our data.
We limited the postoperative follow-up period for blood prod-
uct transfusions to 24 hours to keep this study solely related to
surgery and its requirements for blood product transfusion. Often
postoperative ﬂuid therapy in patients with SAH is guided by
partly controversial “HHH” (hypervolemia, hypertension, hemo-
dilution) treatment to prevent vasospasm (13, 20). Although our
current practice targets normovolemia, the hemodilution induced
by ﬂuid therapy also can require transfusion of blood products
regardless of surgery. It is reported that 36%e47% of patients with
SAH develop anemia (5, 18, 21). The optimal hemoglobin level in
these patients is still debated (9). Higher hemoglobin level may
improve patient outcome (5, 14-16), but simultaneously RBCT it-
self is a risk factor for worse outcome and may increase the risk
of extracerebral complications (11, 19). However, our results
concerning postoperative RBCT cannot be compared directly with
earlier reports because the length of the postoperative period was
not clearly deﬁned; Le Roux et al. (7) reported that 46% of patients
operated on for ruptured and nonruptured aneurysms received
RBCs postoperatively. In that study, high use of RBCs also was
associated with poor-grade SAH in patients. Our demonstrated
intraoperative FFP and platelet transfusion rates of 3.6% and 1.2%,
respectively, can be considered low, but there are limited data for
comparison.
Our study conﬁrms that prevention of rebleeding before the
aneurysm is secured is the key element to minimize the need for
blood product transfusion in patients with SAH. Modern neuro-
surgical techniques using high magniﬁcation of the operating
microscope and frequent use of temporary clipping to facilitate safe
clipping of the aneurysms together with optimal neuroanesthesia
with relatively low systolic blood pressure (systolic blood pressure
w100 mm Hg) are essential to treat these patients successfully (3,
17). Stable hemodynamics, preserved coagulation capacity, and
slack brain with the head elevated above the heart level enable
neurosurgeon to preserve normal anatomy and to prevent access
bleeding during aneurysm clipping. Use of adenosine is a practical
tool in the event of sudden intraoperative rupture of an aneurysm (1,
12). Although the need for RBCs can be urgent, we do not routinely
crossmatch RBCs for patients before aneurysm surgery. When
RBCs are not readily available, the decision to transfuse RBCs is not
automated, but is based on the patient’s real needs. RBCs can be
obtained within 15e20 minutes after the decision to perform RBCT
has been made. In the long run, this approach can result in
considerable economic savings (8).
CONCLUSIONS
The incidence of perioperative transfusion of blood products in
aneurysm surgery is low, and intraoperative RBCT is strongly
related to rupture of an aneurysm. The transfusion of FFP and
platelets is uncommon and seems to be related to preemptive
transfusion in patients on anticoagulation or antiplatelet therapy.
Intraoperative RBCT itself may increase a patient’s risk of an
unfavorable neurologic outcome, but this observed association
warrants further study.
Table 4. Factors Associated with Increased Risk of Unfavorable Outcome at 3 Months
Factor
Logistic Regression Propensity Score Adjusted
OR 95% CI P Value OR 95% CI P Value
Intraoperative RBCT (yes) 5.13 1.53e17.15 0.008 5.12 1.51e17.41 0.009
Intraoperative aneurysm rupture (yes) 1.36 0.73e2.54 0.34 0.96 0.30e3.07 0.96
WNFS classification (increase) 1.97 1.64e2.36 < 0.001 1.94 1.60e2.34 < 0.001
Fisher grade (increase) 1.89 1.23e2.92 0.004 1.76 1.09e2.83 0.02
Preoperative hemoglobin (increase by 1 g/L) 1.01 1.00e1.03 0.20 1.01 1.00e1.03 0.14
Aneurysm size (increase by 1 mm) 1.02 0.96e1.09 0.50 1.01 0.95e1.08 0.74
Age (increase by 1 year) 1.07 1.04e1.10 < 0.001 1.07 1.05e1.10 < 0.001
CI, confidence interval; OR, odds ratio; RBCT, red blood cell transfusion; WFNS, World Federation of Neurological Surgeons.
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Abstract Background: Rupture of an intracranial aneurysm during surgical clipping may have devastating
consequences. Should this happen all methods ought to be considered to stop the bleeding. A short-
term cardiac arrest induced by adenosine could be a feasible method to help the surgeon. We present
our experiences in the administration of adenosine during an intraoperative aneurysm rupture.
Methods: Medical records of patients who underwent surgical clipping of a cerebral arterial
aneurysm were reviewed from 2 university hospitals' operative database in the years 2003 to 2008.
Patients were included in this study if adenosine had been administered during intraoperative rupture
of an aneurysm.
Results: Altogether, 16 of 1014 patients were identified with the use of adenosine during an
intraoperative rupture of an aneurysm. All of the patients had sinus rhythm and normotension before
the rupture of the aneurysm. Twelve patients were administered a single dose of adenosine and 4
multiple boluses for induction of cardiac arrest; the median (range) total dose was 12 (6-18) mg and
27 (18-87) mg, respectively. The clipping of the aneurysm and the recovery of circulation were
uneventful in all cases. In a subgroup analysis according to patient outcome as alive/dead, the pre-
and postoperative neurologic condition correlated with the outcome, whereas adenosine did not have
any effect on the patient outcome.
Conclusion: In a case of a sudden aneurysm rupture, adenosine-induced circulatory arrest could be a
safe option to facilitate clipping of an aneurysm. However, if adenosine is used, a very close
collaboration between the surgeon and the anesthesiologist is required.
© 2010 Elsevier Inc. All rights reserved.
Keywords: Adenosine; Heart arrest; Intracranial aneurysm; Rupture; Spontaneous
1. Introduction
Intraoperative rupture of the cerebral arterial aneurysm
can have undesired consequences. Whether it has an effect
on patient neurologic outcome remains to be determined.
The most recent study suggests, however, that intraoperative
aneurysm rupture does not influence patient outcome [1,18].
Stable intraoperative blood pressure, careful microneurosur-
gical technique, and the application of temporary clips may
minimize the risk of rupture of the aneurysm [2,6,9,13]. In a
case of an aneurysm rupture, adenosine, a short-acting drug
with negative effect on sinoatrial and atrioventricular nodes,
has been used successfully to induce transient cardiac arrest
to stop the bleeding when suction fails to clear the operative
field [10,12,15]. The relatively bloodless field may enable
the surgeon to place temporary or permanent clip under
visual control.
Abbreviations: ECG, electrocardiography; GCS, Glasgow Coma Scale;
GOS, Glasgow Outcome Scale; SAH, subarachnoid hemorrhage
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There are only 3 earlier single-patient case reports with
successful use of adenosine in inducing a transient cardiac
arrest to facilitate clipping of an aneurysm with or without a
rupture [10,12,15]. We analyzed retrospectively the data of
the patients who were administered adenosine during the
intraoperative rupture of a cerebral arterial aneurysm.
2. Methods
Patients with surgical clipping of an intracranial aneu-
rysm were identified from the operative database and records
of Turku and Helsinki University Hospitals over a period of
5.5 years (January 2003-May 2008). These 2 university
hospitals serve southern and western Finland with a
population of 3 million. Patients were included in the
study if there was a rupture of an aneurysm during the
surgery and if they had received adenosine after the rupture.
As the study is of a retrospective nature, approval by the
hospital ethics review committees was not required. The
perioperative treatment protocols of patients with SAH, as
well as of patients with nonruptured cerebral aneurysm, are
similar in both university hospitals [17].
The clinical variables included in the analyses were age,
comorbidities, GCS, Fischer scale, Hunt and Hess scale,
presence of hydrocephalus, location of the aneurysm,
hemodynamics before and after the adenosine, dose of
adenosine, use of vasoactive drugs, number of delayed
ischemic deficiencies, length of stay in the intensive care unit
and in the hospital, patient state at discharge from the
hospital, and GOS. Furthermore, the patients were grouped
according to discharge from the hospital (dead or alive) and
according to outcome (good outcome, GOS 4-5; poor
outcome, GOS 1-3).
2.1. Statistics
The descriptive statistics are shown as mean ± SD or as
median (range) when the parameters were not distributed
normally. The clinical variables and the subgroups (dead/
alive and good outcome/poor outcome) were compared by
paired t test using the SYSTAT 10.2 statistical package
(SYSTAT Software, Inc, San Jose, CA). P b .05 was
considered statistically significant.
3. Results
Altogether, 16 of 1014 patients (Helsinki, 825; Turku,
189) were identified with the use of adenosine during an
intraoperative rupture of an intracranial aneurysm (Table 1).
Fifteen of the patients were admitted to the hospital owing to
a SAH, and one patient was scheduled for an elective
clipping of a basilar aneurysm. Nine of the cerebral
aneurysms were located in the anterior and 7 in the posterior
cerebral circulation (Table 2). Seven of the patients were
previously diagnosed to have hypertension, 2 with coronary
artery disease, and 3 with universal atherosclerosis. The
comorbidities associated with SAH are presented in Table 3.
Fourteen patients had sinus rhythm preoperatively. In one
patient, the preoperative ECG was not found. One patient
with sinus rhythm had supraventricular extrasystolic beats.
Ischemic ECG changes were observed in 4 patients
preoperatively. The preoperative plasma potassium level
was within normal range in all of the patients.
Anesthesia was maintained with propofol and remifenta-
nil in all patients. Ten minutes before the aneurysm rupture
and adenosine bolus, the mean systolic and diastolic blood
pressure levels were 119 ± 14 and 59 ± 10 mm Hg,
respectively, and the mean heart rate was 70 ± 13 per minute.
After intraoperative aneurysm rupture, 12 patients received a
single adenosine bolus, whereas 4 patients received repeated
boluses of adenosine. The median (range) adenosine dose
used for the single bolus was 12 (6-18) mg, whereas the
median total dose for multiple boluses was 27 (18-89) mg.
As measured 10 minutes after the adenosine, the
hemodynamics of the patients were stabilized. At this
stage, the mean systolic and diastolic blood pressure levels
were 113 ± 14 and 57 ± 9 mmHg, respectively, and the mean
heart rate was 74 ± 15 per minute. During the surgery, 13
patients needed an infusion of vasoactive drugs to maintain
adequate blood pressure. Four patients were administered
noradrenalin, 7 patients with phenylephrine, and one patient
required both phenylephrine and dobutamine. All vasoactive
drugs were commenced after the anesthesia induction and
Table 1
Demographics of the data, presented as numbers of patients and means ± SD
Sex (male/female) 6/10 (37.5%/62.5%)
Age 53.1 ± 15.5 y
Height 76.0 ± 9.9 kg
Weight 169.9 ± 7.9 cm
SAH/Elective surgery 15/1
Table 2
Locations of the aneurysms
Aneurysms Numbers (%)
Internal carotid artery 2 (12.5)
Middle cerebral artery 4 (25)
Anterior cerebral artery 1 (6.25)
Anterior communicating artery 2 (12.5)
Posterior cerebral artery 1 (6.25)
Basilar artery 5 (31.25)
Pericallosal artery 1 (6.25)
Table 3
Comorbidities associated with SAH
Yes No
Hydrocephalus 5 11
ECG Ischemia 4 12
Neurogenic pulmonary edema 1 15
DIND 2 13
ECG ischemia indicates myocardial ischemia seen on ECG; DIND, delayed
ischemic neurologic deficiencies.
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infused throughout the surgery. The mean duration of the
surgery was 135 ± 27 minutes.
The mean stay in the intensive care unit was 6.3 ± 4.6
days and in the university hospital was 17.9 ± 11.7 days. The
median (range) postoperative GCS was 9.5 (3-15). The
number of patients discharged alive from the hospital was
12, and 4 died during the hospital stay. Four patients died
later in other hospitals owing to complications related to
SAH. Two patients experienced delayed ischemic neurolog-
ic deficiencies, and one of them died after discharge from the
hospital. The median (range) GOS was 2 (1-5). Five patients
were discharged with GOS of 5, 2 patients with GOS of 4,
one with GOS of 3, and 8 patients with GOS of 1 (died).
Table 4 presents the severity of SAH, administered doses of
adenosine, and GOS.
In subgroup analysis, there was a significant difference in
the median Hunt and Hess score between the patients
discharged alive or dead from the hospital, 3.5 (0-5) and 5 (4-
5) (P b .05), respectively. There was also a significant
difference in the median pre- and postoperative GCS
between the patients discharged alive or dead, 11.5 (3-15)
and 4.5 (3-7) and 14 (4-14) and 4.5 (3-8) (P b .05),
respectively. The Fischer scale, Hunt and Hess score, GCS
on admittance or after the surgery, however, were similar in
the good-outcome (GOS 4-5) and in the poor-outcome (GOS
1-3) groups. The total administered dose of adenosine or the
hemodynamics were not different between any of these
subgroups (P N .05).
4. Discussion
In the present study, we analyzed the hospital records of
16 of 1014 patients who had an intraoperative rupture of a
cerebral aneurysm with the short-term adenosine-induced
circulatory arrest facilitating the clipping. The decision to
give adenosine was made in cooperation with the neurosur-
geon and the anesthesiologist. The final clipping of the
aneurysm as well as the restoration of systemic circulation
was successful in all cases. We did not observe any
immediate or late adverse events related to the administra-
tion of adenosine.
Adenosine has a very short negative dromotropic and
chronotropic effect on cardiac sinoatrial and atrioventricular
nodes, and it is usually indicated in paroxysmal supraven-
tricular tachyarrhythmia. The administration of adenosine in
patients with normal sinus rhythm induces a rapidly
reversible cardiac arrest. The intravascular half-life of
adenosine at the physiologic level is less than a second.
The mechanism of action of adenosine in cardiac muscle is
hyperpolarization after its binding to A1 receptors and
opening of potassium channels. Adenosine also decreases
intracellular cyclic adenosine monophosphate, which inhi-
bits calcium entry into the cell [3,14,16].
In the current study, the majority of the patients
presented a cardiac arrest after a single dose of adenosine
(median, 12 mg). This median dose is in accordance with
the recommended doses of 6 to 12 mg for supraventricular
tachyarrhythmias [7,8]. However, 4 of 16 patients were
administered adenosine more than once and the median
cumulative dose was considerably higher, 27 mg. As
assessed retrospectively, there may have been requirements
for a prolonged cessation of circulation because of surgical
reasons or the ineffectiveness of adenosine to induce
cardiac arrest during normal sinus rhythm. Although none
of the 16 patients had unstable hemodynamics nor
abnormal arrhythmias after the restoration of spontaneous
circulation, repeated doses of adenosine might be given
only under extremely close collaboration between the
surgeon and the anesthesiologist. For instance, Heppner et
al [12] reported administration of a high dose of adenosine,
that is, 36 mg, in one patient resulting in prolonged cardiac
Table 4
Severity of SAH and outcome of patients receiving adenosine
Patient GCS Fischer Hunt and Hess Temporary clip Occlusion time Adenosine (mg) GOS
1 13 3 4 No 18 1
2 15 3 2 No 6 5
3 5 3 4 No 18 1
4 6 4 5 Yes 6 min 28 s 9 4
5 5 4 5 Yes Not known 12 1
6 10 4 4 No 16 1
7 15 1 1 Yes Not known 12 5
8 3 4 5 Yes 19 min 87 1
9 3 3 5 Yes Not known 9 3
10 7 4 5 Yes Not known 12 1
11 15 4 2 Yes 9 min 55 s 18 5
3 min 22 s
12 4 4 5 Yes Not known 12 1
13 15 Elective Elective No 9 5
14 15 3 2 Yes 6 min 18 s 12 5
15 3 4 5 Yes Not known 36 1
16 10 3 3 Yes 5 min 12 4
Glasgow Outcome Scale: 5 indicates good recovery; 4, moderate disability; 3, severely disabled; 2, vegetative state; 1, death.
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arrest up to 52 seconds. Adenosine has also been reported
to induce ventricular tachycardia or torsades des pointes
[5,11]. Patients in our study received on average
significantly smaller doses of adenosine, and cardiac
standstills were shorter as well. The fact that most of our
patients (n = 13/16) did not have coronary artery disease
nor had ischemia in ECG (n = 12/15) preoperatively might
have also favored the uneventful restoration of circulation
after adenosine.
In the current study, 4 patients with SAH were treated
perioperatively with intravenous calcium channel antagonist
nimodipine to prevent vasospasm. Calcium channel antago-
nists and also dipyridamol may inhibit adenosine metabo-
lism and reuptake to cell [11]. Although the adenosine-
induced cardiac arrest of the 4 patients with SAH was
comparable to that of the patients not on intravenous
nimodipine, one should be aware of the possible interaction
between nimodipine and adenosine: nimodipine might
potentiate the effect of adenosine [4]. The possible
interactions of adenosine with propofol, inhaled anesthetics,
or opioids are unknown.
Five (31.25%) of 16 patients who were given adenosine
underwent surgery of basilar artery aneurysm. This probably
refers to the fact that these operations are technically the
most challenging ones. This is also supported by other case
reports. Groff et al [10] used 3 consequent doses of
adenosine to facilitate the placement of a permanent clip to
the nonruptured basilar artery aneurysm, whereas the report
by Heppner et al [12] describes a case where 3 relatively high
and consequent doses of adenosine were used to help the
surgeon to place a permanent aneurysm clip on the basilar
aneurysm, because the attempt to place a temporary clip had
failed. Nussbaum et al [15] gave a single dose of adenosine
to control the bleeding of a ruptured anterior communicating
artery aneurysm.
The present report has limitations. As all the anesthetic
records were hand written, and the study was retrospective,
no details of the blood pressure or heart rate immediately
after adenosine boluses could be identified. This may be
related to the emergency situation with the intraoperative
aneurysm rupture. However, we believe if there had been
delayed restoration of spontaneous circulation or major
hemodynamic instability requiring high doses of vasoactive
agents, we could have been able to observe these adverse
events in the individual patient's records. We also believe
that circulatory arrest facilitated the clipping procedure
enabling the neurosurgeon to place a temporary or final clip
in a clear field to stop the bleeding, although we lack the
neurosurgeon's specific grading of the benefit of the
administration of adenosine in single patients. After initial
clipping, the clips may be repositioned for optimal occlusion
of the aneurysm.
According to our data, there were no differences in any of
the measured scales (Hunt and Hess, GCS, Fisher's scale) as
the patients were grouped according to good or poor
outcome (GOS). However, both the preoperative Hunt and
Hess scoring and GCS seemed to be good predictors of in-
hospital survival when the patients were grouped at hospital
discharge as dead or alive. As the dose of adenosine was
comparable in these subgroups, the circulatory arrest
induced by adenosine does not seem to have had a
deleterious effect on patient outcome. We started to use
adenosine soon after it was first introduced in this indication
by Groff et al [10] in 1999. Since then, surgical techniques
have also changed; especially, the use of temporary clips has
become more frequent. Hence, comparison with older
material may not be justified in evaluating the effect of
adenosine on outcome.
We conclude that adenosine can be safely administered
during surgery of a cerebral arterial aneurysm to patients
who experience a sudden, uncontrolled bleeding without
previous sinoatrial conduction abnormality. Good collabo-
ration between the neurosurgeon and the anesthesiologist is
mandatory. The indications of adenosine during intracranial
aneurysm surgery are recommended to be discussed
preoperatively with the neurosurgeon.
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Abstract Normal blood coagulation is essential in pediatric
neurosurgery because of the risk of abundant bleeding, and
therefore it is important to avoid transfusion of ﬂuids that
might interfere negativelywith the coagulation process. There
is a lack of transfusion guidelines in massive bleeding with
pediatric neurosurgical patients, and early use of blood com-
pounds is partly controversial. We describe two pediatric
patients for whom fresh frozen plasma (FFP) infusion was
started at the early phase of brain tumor surgery to prevent
intraoperative coagulopathy and hypovolemia. In addition to
the traditional laboratory testing, modiﬁed thromboelastom-
etry analyses were used to detect possible disturbances in
coagulation. Early transfusion of FFP and red blood cells
preserved the whole blood coagulation capacity. Even with
continuous FFP infusion, ﬁbrin clot ﬁrmness was near to
critical value at the end of surgery despite increased preop-
erative values. By using FFP instead of large amounts of
crystalloids and colloids when major blood loss is expected,
blood coagulation is probably less likely to be impaired. Our
results indicate, however, that the capacity of FFP to correct
ﬁbrinogen deﬁcit is limited.
Keywords Fluid therapy  Transfusion  Fresh frozen
plasma  Red blood cells  Brain tumor  Pediatric
neurosurgery
Introduction
In pediatric brain tumor surgery, the patient is often at risk
for abundant bleeding. Normal blood coagulation is
essential, and transfusion of ﬂuids must not disturb this
homeostasis. All artiﬁcial colloids and mannitol, in addi-
tion to their dilutional effects, decrease whole blood clot
strength, predisposing patients to bleeding [1–3].
Transfusion protocols in massive bleeding are well
documented in adult populations [4–6]. Pediatric patient
guidelines are, however, scarce, and those for adults are not
directly transferable to children [7]. We describe two cases
in which an early fresh frozen plasma (FFP) infusion was
used in brain tumor surgery to prevent intraoperative
coagulopathy and hypovolemia. In addition to traditional
laboratory testing, we used modiﬁed thromboelastometry
analyses to trace possible blood coagulation disturbances.
Case report
Patient 1
A previously healthy 10-month-old boy (height 78 cm,
weight 9.9 kg) had a richly vascularized left parieto-occipital
tumor. The tumor extended to the mesencephalon and
hypothalamus, causing a midline shift and hydrocephalus.
After induction, anesthesia was maintained with pro-
pofol and remifentanil infusions. The surgery took place
with the patient in a sitting position. After a left parame-
dian parieto-occipital craniotomy, an occipital interhemi-
spheric ﬁssure was used to approach the tumor. After tumor
debulking, the anaplastic meningioma was gradually dis-
sected from the surrounding neurovascular structures and
completely removed.
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Addition to Ringer acetate solution, FFP infusion at the
rate of 20 ml/h was started after anesthesia induction.
50 ml mannitol (150 mg/ml) was administered. Blood loss
during surgery was 750 ml (300 ml within 25 min), and
the patient received a total of 500 ml red blood cells (RBC)
during surgery and another 60 ml in the intensive care unit
(ICU), with no need for platelet transfer. The total amount
of ﬂuids infused during surgery (blood compounds and
crystalloids) was 1,504 ml, and ﬂuid loss (blood and urine)
was 1,090 ml. The patient woke up and was extubated
without complications 120 min after the operation.
Patient 2
A 5-month-old boy (height 67 cm, weight 7 kg) developed
symptoms of increased intracranial pressure. Magnetic
resonance imaging (MRI) study revealed a massive tumor
in the left pontocerebellar area causing pressure to the
brainstem.
Propofol and remifentanil infusions maintained the
anesthesia. Surgery took place with the patient in a park
bench position with head attached to the Mayﬁeld device.
The neurosurgeon performed a left suboccipital crani-
otomy. After tumor debulking, he dissected and completely
removed the lesion from the surrounding cerebrovas-
cular structures. The tumor was ependymoma gradus
II–III.
Together with 0.9 % sodium chloride solution with 5 %
glucose (20 ml/h), FFP infusion was started after induction
(240 ml in total). 25 ml mannitol (150 mg/ml) was given.
Intraoperative blood loss was 380 ml, and the patient
received a total of 250 ml RBC during surgery and another
60 ml in the ICU, with no need for platelet transfer. The
total amount of ﬂuids infused during surgery (blood com-
pounds and crystalloids) was 870 ml and ﬂuid loss (blood
and urine) 960 ml. Two 250-mg boluses of tranexamic acid
were given during surgery. The patient was kept sedated in
controlled ventilation in the ICU until the ﬁrst postopera-
tive morning.
Laboratory analyses
The results of laboratory tests are given in Table 1. Both
patients had mild anemia and abnormally high platelet
count, but thromboplastin time values (PT-%, normal
70–130 %) fell within normal limits.
Four different thromboelastometry tracings were used:
Intem (intrinsic pathway), Extem (extrinsic pathway),
Fibtem (platelet function inhibition by cytochalasin D),
and Aptem (added aprotinin to detect hyperﬁbrinolysis).
In Extem and Fibtem analyses, coagulation time
(CT), clot formation time (CFT), alpha-angle, and maxi-
mum clot ﬁrmness (MCF) were within normal reference
ranges before the surgery, but both patients had increased
ﬁbrin MCF preoperatively (Fibtem). Maximum lysis
(ML), indicative of ﬁbrinolytic activity, was 21 % (normal
\15 %) in both patients in preoperative Extem analysis.
However, MCF was comparable between Aptem and
Extem analyses.
Clot formation time was longer in all samples in com-
parison with the preoperative values (Fig. 1). MCF was
slightly decreased in Intem and Extem analyses in
comparison with preoperative values (Fig. 2). Decrease in
MCF in Fibtem analysis was more profound and reached
a critical value of 8 mm at the end of surgery in patient 2
(Fig. 3). Maximum lysis (ML) diminished gradually in
both patients, showing least activity at 2 h after the surgery
in patient 1 (ML 1 %).
Thromboelastometry analyses in the ﬁrst postoperative
morning were similar to preoperative values. Fibrin clot
ﬁrmness was increased in both patients, i.e., leaning
slightly toward hypercoagulopathy. Maximum lyses (ML)
were within normal reference ranges.
Discussion
Both patients were preoperatively considered to have a
signiﬁcant risk of major blood loss during neurosurgery.
Table 1 Results of laboratory
and standard coagulation tests
Hb hemoglobin, Hct hematocrit,
Eryt erythrocytes, PT
prothrombin time, P1 patient 1,
P2 patient 2
Hb (g/dl) Hct (%) Platelets (E9/l) PT (%)
P1 P2 P1 P2 P1 P2 P1 P2
Baseline 9.1 10.1 28 31 656 560 122 136
Intraoperative 10.59 8.3 8.5 25 24 633 316
Intraoperative 12.20 12.3 35 436 93
End of surgery 13.32 10.7 30 327 93
3 h after operation 9.4 26 292 103
5 h after operation 12.6 35 220
9 h after operation 8.5 24 279
First postoperative day 9.8 11.9 27 34 301 236 120 102
J Anesth (2012) 26:770–774 771
123
Thromboelastometry analysis showed that early transfusion
therapy with FFP and RBC preserved the whole blood
coagulation capacity. Interestingly, ﬁbrin clot ﬁrmness was
near the critical value at the end of surgery, despite
increased preoperative ﬁbrin clot ﬁrmness.
Transfusion guidelines concerning pediatric patients
address very little intraoperative ﬂuid management during
excessive blood loss. The emphasis is more on critically ill
patients and patients suffering from a chronic coagulation
deﬁcit [8–10]. Although transfusion guidelines for adults in
massive bleeding are leaning toward the use of an
increased ratio of FFP and platelets in relationship to red
blood cells [11], the general view with pediatric patients
still is that crystalloids are the ﬁrst-line solutions and dif-
ferent blood compounds should only be administered when
coagulation deﬁcit, revealed by laboratory testing, has
developed [8, 9]. This is a challenge when treating pedi-
atric neurosurgical patients. Hypovolemia may develop
quickly because of the patient’s low blood volume. Second,
abrupt massive bleeding is possible, in which situation
laboratory testing and thromboelastometry analysis are too
slow to guide transfusion of ﬂuids.
To prevent the development of coagulation disturbance
and hypovolemia intraoperatively, we started FFP infusion
at the beginning of the surgery before major bleeding could
occur. Even with continuous FFP infusion, a decrease in
PT-% was evident with both patients (25–29 % percentage
points during surgery). However, relatively minor changes
in CT and CFT values in Intem and Extem analysis
indicate that a marked deﬁcit of coagulation factors did not
developed during surgery. Our results suggest that without
an early FFP infusion, or with crystalloid or colloid infu-
sions, a clinically relevant lack of coagulation factors
would have occurred during the operations.
Efﬁcacy of FFP to correct ﬁbrinogen deﬁcit is limited.
Decrease in clot ﬁrmness in Fibtem analyses was also
evident in both our cases, which suggests that our patients
would probably have beneﬁted from increment of ﬁbrino-
gen if surgical hemostasis would not have been satisfac-
tory. Haas and co-workers [12] showed that the
administration of ﬁbrinogen during craniosynostosis repair
avoided the need for FFP transfusion; instead, colloids
were used to compensate blood loss. Use of colloids in
massive bleeding, however, is not unambiguously sup-
ported, because of their negative interference with blood
coagulation [13], especially with mannitol [2]. We gave
patient 2 tranexamic acid because of the increased maxi-
mum lysis (21 %) preoperatively and positive in vitro
effect of aprotinin (Aptem) on clot strength in the intra-
operative analysis. A single bolus of tranexamic acid also
reduces bleeding and the need for red blood cell transfusion
without extreme ﬁbrinolytic activity in craniosynostosis
operations [14].
Fig. 1 Clot formation time (CFT) in Intem (normal reference range,
30–110 s) and Extem (34–159 s) analyses
Fig. 2 Maximum clot ﬁrmness (MCF) in Intem (normal reference
range, 50–72 mm) and Extem (50–72 mm) analyses
Fig. 3 Maximum clot ﬁrmness (MCF) in Fibtem analysis
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A postoperative hypercoagulable state is a common
ﬁnding in children undergoing brain surgery [15], and
enhanced coagulation in thromboelastometry analysis is
seen after relatively minor blood loss during craniotomy
[15]. The speciﬁc deﬁnition of hypercoagulability and its
effect on the risks of either thrombosis, or bleeding, are still
unclear in craniotomy patients [16]. Our patients had
increased MCF in Fibtem analyses preoperatively, but in
Extem analyses MCF were within the normal reference
range. Hypercoagulability, i.e., increased MCF in Fibtem,
however, decreased during the operations, and the critical
values for ﬁbrin clot ﬁrmness were almost reached at the
end of surgery. A decrease in clot strength is associated
with bleeding complications [13].
Thromboelastometry (ROTEM) allows a dynamic
evaluation of the entire coagulation process and distin-
guishes intrinsic and extrinsic coagulation pathways from
pure ﬁbrin formation. The use of thromboelastometry
analysis in pediatric surgical patients is well documented
[14, 17, 18]. Recent Cochrane analysis states, however, that
there is still a lack of evidence that use of ROTEM would
decrease morbidity or mortality [19].
Allergic reactions, transfusion-related acute lung injury
(TRALI), and infections are the major concerns related to
transfusion of FFP and other blood components [20]. Virus
inactivation and reduction of HLA and other antibodies by
pooling have led to reduced risks of transfusion-related
adverse effects. Instead of traditional FFP, we used Octa-
plas, which is a pharmaceutical product that has gone
through solvent-detergent treatment and is pooled from
approximately 1,000 donors.
Perioperative ﬂuid administration should be planned in
advance when treating pediatric neurosurgical patients, and
possible detected disturbances in blood coagulation should
be handled before surgery. The excessive use of crystal-
loids and colloids in itself disturbs blood coagulation, and
therefore early use of FFP is a noteworthy option when
major blood loss is expected. Thromboelastometry offers
an additional tool to observe possible disturbances in blood
coagulation and to guide administration of ﬁbrinogen or
tranexamic acid.
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Abstract
Background Hypertonic saline (HS) is an alternative to
mannitol for decreasing intracranial pressure in traumatic
brain injury and before craniotomy. Both HS and mannitol
may interfere with blood coagulation but their inﬂuence on
coagulation has not been compared in controlled situations.
Therefore, we evaluated different strengths of HS and 15%
mannitol on blood coagulation in vitro.
Methods Citrated fresh whole blood, withdrawn from 10
volunteers, was diluted with 0.9%, 2.5%, or 3.5% HS or
15% mannitol to make 10 vol.% and 20 vol.% hemodilu-
tion in vitro. The diluted blood and undiluted control
samples were analyzed with thromboelastometry (RO-
TEM) using two activators, tissue thromboplastin without
(ExTEM) or with cytochalasin (FibTEM).
Results In the FibTEM analysis, maximum clot ﬁrmness
(MCF) was stronger in the 2.5% HS group than in the
mannitol group after both dilutions (P < 0.05). In the
ExTEM analysis, clot formation time (CFT) was more
delayed in the mannitol group than in the 0.9%, 2.5%, or
3.5% HS groups in 20 vol.% hemodilution (P < 0.05).
MCF was weaker in the mannitol group than in the other
groups after 20 vol.% dilution (P < 0.05). MCF was also
weaker in the 3.5% than in the 0.9% saline group after
20 vol.% dilution (P < 0.05).
Conclusions Blood coagulation is disturbed more by 15%
mannitol than by equiosmolar 2.5% saline. This distur-
bance seems to be attributed to overall clot formation and
strength but also to pure ﬁbrin clot ﬁrmness. This saline
solution might be more favorable than mannitol before
craniotomy in patients with a high risk of bleeding.
Keywords Hypertonic saline  Mannitol  Coagulation 
Traumatic brain injury  Craniotomy  Neurosurgery
Introduction
Mannitol has been the agent of choice in traumatic brain
injury when osmotherapy has been needed to decrease
intracranial pressure (ICP). It is also widely used in the
same indication in neurosurgery with patients having a
brain tumor or subarachnoid hemorrhage [1, 2].
Hypertonic saline (HS) can be used in a treatment of
increased ICP in traumatic brain injury during neuroin-
tensive care. HS also prevents brain swelling during
emergency craniotomy and may be an alternative to man-
nitol. Furthermore, HS is often used to instantly increase
intravascular volume in patients with bleeding shock [3–6].
Extensive use of HS can lead to hypernatremia [7]. Earlier
studies suggest that HS is equally effective or even better
than mannitol in reducing brain swelling in patients
undergoing craniotomy [8–15]. However, due to variable
study protocols, e.g., regarding osmolarity and adminis-
tered volumes, deﬁnite conclusions about differences in
physiological responses or occurrence of untoward effects
cannot be drawn.
The results were presented at the ESICM 2010 Meeting, Barcelona,
Spain, Oct 9–13, 2010.
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Previous in vitro studies have demonstrated that both
mannitol and HS interfere negatively with various com-
ponents of blood coagulation [16–20]. Mannitol (15%)
alone interferes with blood coagulation by reducing clot
strength [20]. Mannitol (15%) when combined with
hydroxyethyl starch causes a disturbance in ﬁbrin forma-
tion and, consequently, in blood coagulation in 10 and
20 vol.% dilution. HS in different concentrations (3–7.5%)
disturbs both ﬁbrin formation and platelet function in the
coagulation process.
The purpose of the present study was to compare the
effect equimolar and equivolemic solutions of HS and
mannitol on blood coagulation in vitro. Our hypothesis was
that HS with low concentrations of sodium chloride would
impair blood coagulation less than 15% mannitol.
Methods
The study protocol was approved by the institutional ethics
committee. Written informed consent was obtained for
blood donation for the study from 10 (three women, seven
men) apparently healthy, non-smoking volunteers aged
21–36 years. No medication was allowed 5 days prior the
study day. Fasting of 6 h was required before the blood test.
Thirty milliliter of venous blood was taken from the
cubital vein via 20 G needle into three 10-ml glass tubes
(Becton–Dickinson, Vacutainer, Heidelberg, Germany),
each containing 3.2% buffered citrate. Citrated whole
blood was then diluted with the study solutions to make 0,
10, and 20 vol.% concentrations of the solutions.
The study solutions were 0.9% saline (Natriumklorid
Braun 9 mg/ml, reported osmolarity 300 mOsm/l), 2.5%
saline (1 part Natriumklorid Braun 234 mg/ml + 13.1
parts Natriumklorid Braun 9 mg/ml), 3.5% saline (1 part
Natriumklorid Braun 234 mg/ml + 7.6 parts Nat-
riumklorid Braun 9 mg/ml) and 15% mannitol (Mannitol
Braun 150 mg/ml infusion ﬂuid). Manufacturer of Man-
nitol Braun 150 mg/ml infusion ﬂuid reports that
theoretical osmolarity of the ﬂuid is 825 mOsm/l. Calcu-
lated osmolarity for 2.5% saline is 830 mOsm/l and for
3.5% saline 1160 mOsm/l.
Two four channel thrombelastometry devices (Rotem,
Pentafarm AG, Basle, Switzerland) were used to make
coagulation analyses within 2 h of blood withdrawal. After
re-calciﬁcation (Star-TEM, Pentafarm AG, Basle, Swit-
zerland) of the samples the coagulation process was
facilitated by two different activators, tissue thrombo-
plastin without (ExTEM, Pentafarm AG, Basle,
Switzerland) or with cytochalasin (FibTEM, Pentafarm
AG, Basle, Switzerland). The development of coagulation
process was registered during 30 min period. The mea-
sured coagulation parameters for ExTEM were clotting
time (CT), clot formation time (CFT), maximum clot
ﬁrmness (MCF), and alpha angle (clot formation rate,
denotes the rate of the formation of a solid clot). Only MCF
was measured in FibTEM analysis.
The Rotem parameters are shown in Fig. 1. CT reﬂects
the time from the start of the measurement until the start of
clot formation. CFT refers to the time from the beginning
of clot formation until a clot ﬁrmness of 20 mm has been
reached. Alpha angle is the angle between the central line
CFT = Clot Formation Time (sec)
α- angle (°)
MCF = Maximum Clot Firmness (mm)
Clot Quality
Maximum Lysis (%)
CT = Clotting Time (sec)
A5 = Clot Firmness (mm)
5 minutes after CT
AX = Clot Firmness (mm)
x minutes after CT
Fig. 1 Rotem parameters
Neurocrit Care (2011) 14:238–243 239
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and the tangent of the curve at the amplitude point of
2 mm. MCF describes the strength of the clot.
Hemoglobin concentration (Hb), hematocrit value (hct),
and platelet count were determined in all the study dilu-
tions and the undiluted control samples (Cell-Dyn 610
Haematology Analyser, Seguoia-Turner Corporation,
Mountain View, CA, U.S.A).
The number of volunteers was based on our earlier data
[21]. In a cross-over study setting, eight volunteers would
be needed to discover greater than 1 standard deviation
(SD) difference in MCF between the equiosmolar HS and
mannitol groups of similar vol.% dilution (alpha error
0.05). The differences between the groups were analyzed
by ANOVA followed by t-test or Tukey–Kramer for paired
comparisons. The results are shown as mean with standard
deviations (SD).
Results
All the study solutions with the same vol.% hemodilution
induced a comparable decrease in the hematocrit. Platelet
count was different between the study solutions in
10 vol.% dilution (Table 1). CT and CFT measurements
(ExTEM) for one 20 vol.% dilution sample were unsuc-
cessful and, therefore it was excluded (N = 9 for CT and
CFT).
ExTEM analysis
CT
Clotting time (CT) for mannitol was prolonged in both
study dilutions (10 and 20 vol.%) when compared with
control (P < 0.05), whereas other study solutions (0.9%,
2.5%, and 3.5% saline) showed no difference (Table 2).
Alpha-Angle (Clot Formation Rate)
Alpha-angle was smaller in the 15% mannitol group than in
the 0.9% or 3.5% saline group after 10 vol.% dilution
(P < 0.05). In 20 vol.% hemodilution, alpha-angle was
also more decreased in the 15% mannitol group than in the
0.9%, 2.5%, or 3.5% saline groups (P < 0.05).
Table 1 Hemodilution data
Laboratory result Mannitol
n = 10, each
S0.9%
n = 10, each
S2.5%
n = 10, each
S3.5%
n = 10, each
P values Control
n = 10
hct (%)
10% 36.8(3.0) 36.9(3.2) 36.6(3.0) 36.5(2.9) 0.2043 40.9(3.2)
20% 32.6(2.4) 32.8(2.9) 32.7(3.2) 32.4(3.3) 0.4839
Platelet (9 103/ll)
10% 141(71) 138(51)* 166(66) 169(73) 0.0431 145(54)
20% 143(58) 146(61) 143(68) 166(87) 0.2073
All values are signiﬁcantly (P < 0.05) different from control values (paired t-test)
* P < 0.05 compared with mannitol, 2.5% HS and 3.5% HS
Table 2 Clotting time (CT) and clot formation time (CFT)
ExTEM Mannitol
n = 10
0.9% HS
n = 10
2.5% HS
n = 10
3.5% HS
n = 10
P values Control
n = 10
CT (s)
n = 10 10% 87.6(14.5)* 63.1(15.4) 73.7(25.6) 76.8(47.9) 0.3032 58.7(9.8)
n = 9 20% 89.8(22.9)* 77.2(33.0) 56.0(7.9) 84.8(44.9) 0.0765 60.8(7.7)
CFT (s)
n = 10 10% 172.5(103.3)# 123.4(86.1) 137.4(82.1) 129.2(62.0) 0.0307 119.6(59.7)
n = 9 20% 341.4(241.6)* 134.0(89.6) 167.2(94.9)* 216.9(97.8)* 0.0002
* P < 0.05 compared with control
# P < 0.05 compared with 0.9% HS (CFT)
 P < 0.05 compared with 0.9% HS, 2.5% HS and 3.5% HS (CFT)
Values are mean (SD); analyzed by repeated measure ANOVA followed with Tukey–Kramer’ post hoc test, within each dilution group
240 Neurocrit Care (2011) 14:238–243
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CFT
Clot formation time (CFT) was more delayed in the 15%
mannitol group than in the 0.9%, 2.5%, or 3.5% saline
groups in 20 vol.% hemodilution (P < 0.05).
MCF
Maximum clot ﬁrmness (MCF) was similar with all the
study solutions after 10 vol.% dilution, but after 20 vol.%
dilution MCF was weaker in the 15% mannitol group than
in the other groups (P < 0.05). MCF was also weaker in
the 3.5% saline than in the 0.9% saline group after
20 vol.% dilution (P < 0.05) (Table 3).
FibTEM Analysis
MCF
There was no difference in MCF between the study solu-
tions in 10 vol.% dilution and the control, but MCF was
signiﬁcantly weaker in the 15% mannitol group in
20 vol.% dilution than in the control group (P < 0.05).
When comparison was made between each study solution
there was a signiﬁcant difference in MCF between 15%
mannitol and 2.5% saline both in 10 vol.% and 20 vol.%
dilution 10.2(3.0) vs. 12.3(4.1) and 6.8(2.5) vs. 11.5(3.3),
respectively, P < 0.05) (Table 4).
Conclusion
Our results indicate that 2.5% saline in 10 vol.% and
20 vol.% dilutions impairs blood coagulation less than
equiosmolar 15% mannitol in vitro. An increase in
concentration of sodium chloride to 3.5%, however,
resulted in weaker coagulation.
Contrary to traditional laboratory coagulation test,
thromboelastometry is a method allowing dynamic evalu-
ation of coagulation process [22]. In this study, two
different activators (ExTEM and FibTEM) were used in
thromboelastometry analysis to further evaluate the nature
of coagulation disturbance. As FibTEM analysis inhibits
platelet function, it allows the assessment of the ﬁbrinogen
component in coagulation process.
Overall, our ﬁnding in this study was that 15% mannitol
causes more severe disturbance in blood coagulation than
any of the other study solutions, including 0.9% saline.
This difference between 15% mannitol and other solutions
could already be seen when the dilution was 10 vol.%, but
was more clear in 20 vol.% dilution. The results showed
that not only is the coagulation process slower but the
forming clot is weaker as well, when the dilution is made
with 15% mannitol. The difference in MCF in FibTEM
analysis between 15% mannitol and other study solutions
suggests that coagulation disturbance caused by mannitol is
possibly a result from ﬁbrin poor clot formation. Our
ﬁnding of mannitol deteriorating effect on blood coagula-
tion is in line with an earlier in vitro study [20]. The main
focus of that study was to evaluate the effect of mannitol on
whole blood coagulation when combined either with
Ringer’s acetate or hydroxyethyl starch, but the results
show that mannitol alone affected blood coagulation in
10 vol.% and 20 vol.% dilution.
As earlier experimental studies have indicated, HS has
anticoagulant effects [16–19]. It is unclear, however, at
which sodium chloride concentration level the ﬂuid itself
starts to impair coagulation. Our results support the pre-
vious ﬁndings of anticoagulant feature of HS. Furthermore,
we discovered that the use of 3.5% saline resulted in
weaker clot when compared to 0.9%, but similar difference
Table 3 Maximum clot ﬁrmness (MCF) and alpha angle
ExTEM Mannitol
n = 10
0.9% HS
n = 10
2.5% HS
n = 10
3.5% HS
n = 10
P values Control
n = 10
MCF (mm)
10% 49.0(7.9)* 47.3(6.4)* 50.7(7.6)* 49.3(5.5)* 0.3638 54.8(8.3)
20% 42.3(7.9)*# 51.2(6.5)** 48.2(6.4)* 47.8(6.9)* <0.0001
Alpha ()
10% 62.2(10.1)* 67.5(10.3) 65.4(10.0) 66.5(7.9) 0.0049 67.9(8.6)
20% 44.0(13.8)*# 65.5(10.3)** 61.8(10.4)* 57.3(8.5)* <0.0001
* P < 0.05 compared with control
# P < 0.05 compared with 0.9% HS, 2.5% HS and 3.5% HS
 P < 0.05 compared with 0.9% HS and 3.5% HS
** P < 0.05 compared with 3.5% HS
Values are mean (SD). P values: analyzed by repeated measure ANOVA followed with Tukey–Kramer’ post hoc test, within each dilution group
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was not found between 2.5% saline and 0.9% saline. This
indicates that an increment in concentration potentates the
negative effect which HS exerts on the coagulation process.
There are several earlier clinical studies comparing the
use of mannitol and HS in neurosurgical patients both in
the intraoperative setting and in the neurointensive care.
However, none of these studies have compared the effects
of mannitol and HS on whole blood coagulation. Instead,
the focus has been on what effect these two solutions have
on ICP, hemodynamics, and acid base balance [8–15]. The
results of these studies have been difﬁcult to interpret, and
only in one study the osmolarity and the volume have been
the same for both solutions [8]. In that particular study,
Rozet and coworkers concluded that 20% mannitol and 3%
saline had similar effect on brain relaxation during crani-
otomy. Both solutions caused a similar increase in blood
osmolarity lasting for 6 h. Other studies, where either the
osmolarity or the volume of the study solutions have been
different, have shown that HS is equally effective or even
better in reducing ICP or brain swelling.
Apart from the demonstrated differences in the effect on
coagulation between mannitol and HS, the risk of certain
clinically important side-effects of these solutions may
inﬂuence the choice of solution in critically ill patients.
Mannitol can cause hyponatremia and lactatemia [8].
Mannitol increases urine output which can lead to a neg-
ative ﬂuid balance [10, 13]. A more serious complication of
mannitol is acute renal failure [23, 24]. The osmotic
response to mannitol treatment seems to be variable.
Moreover, there is a high risk of a rebound increase in ICP
after repeated doses of mannitol if the blood brain barrier
(BBB) is damaged [25, 26]. HS boluses or infusions, on the
other hand, can result in hypernatremia which often is
associated with hyperchloremic metabolic acidosis. How-
ever, HS therapy rarely causes acute renal failure [7].
Although BBB is practically impermeable to HS and
mannitol, an impaired BBB can cause a leakage of both
sodium and mannitol into the cerebrospinal ﬂuid [8].
As normal blood coagulation is essential in neurosur-
gery, any treatment method that could impair coagula-
tion should be avoided. Our results indicate that from a
hemostatic point of view 2.5% saline might be more suit-
able than equiosmolar 15% mannitol in neurosurgery or
neurointensive care when ﬂuid therapy is needed to reduce
ICP or brain swelling. Obviously, there is a need to
substantiate our in vitro ﬁndings clinically in large neuro-
surgical patient materials.
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Effect of Arterial Blood Pressure on the Arterial to End-tidal
Carbon Dioxide Difference During Anesthesia Induction
in Patients Scheduled for Craniotomy
Teemu Luostarinen, MD,* O¨zlem Korkmaz Dilmen, MD,w
Tomohisa Niiya, MD, PhD,z and Tomi Niemi, MD, PhD*
Background: Before obtaining results of arterial blood gas
analysis in mechanically ventilated patients undergoing neuro-
surgery, the volume of ventilation is primarily adjusted
according to endtidal CO2 (EtCO2). We characterized the
impact of various arterial blood pressure changes on arterial
PCO2 (PaCO2) to EtCO2 diﬀerences (PaCO2-EtCO2) in patients
anesthetized for craniotomy.
Methods: Seventy-two elective craniotomy patients were enrolled
in this prospective study. Noninvasive blood pressure was
measured before anesthesia induction. Anesthesia was induced
with thiopental, rocuronium or suxamethonium, and fentanyl and
was maintained with inhaled anesthetics or propofol and
remifentanil. Volume-controlled ventilation was adjusted after
intubation according to the clinical judgment. The ﬁrst arterial
blood gas analysis was taken just before the head pinning.
Systolic, diastolic, and mean arterial blood pressures (MAP) and
heart rate were registered after intubation every 5 minutes until the
head pinning.
Results: PaCO2-EtCO2 correlated positively with percentage
diﬀerence between MAP awake at arrival in operating room and
during arterial CO2 determination (P=0.0008, r=0.388). In
analysis according to a MAP decrease of less than 20% (n=17),
20% to 29% (n=24), 30% to 35% (n=16), and more than
35% (n=15), the mean (SD) PaCO2-EtCO2 was greater in
patients with MAP decrease of over 35% or 30% to 35% than in
patients with MAP decrease of less than 20%. The mean (SD)
absolute values of the PaCO2-EtCO2 were 0.96 (0.43) kPa or
0.85 (0.31) kPa versus 0.55 (0.24) kPa, respectively (P<0.05
between categories). Mean EtCO2 was not diﬀerent in the
various MAP diﬀerence categories, but PaCO2 was greatest
when MAP decreased more than 35% (P<0.05).
Conclusions: There was a positive correlation between PaCO2-
EtCO2 and MAP decrease shortly after induction of anesthesia.
PaCO2-EtCO2 is recommended to be interpreted together with
change in MAP during early phase of neuroanesthesia to
guarantee optimal mechanical ventilation.
Key Words: hemodynamics, blood pressure, end-tidal carbon
dioxide, arterial carbon dioxide, neurosurgery
(J Neurosurg Anesthesiol 2010;22:303–308)
During general anesthesia, end-tidal CO2 (EtCO2) isroutinely monitored to assess alveolar ventilation
and arterial CO2 partial pressure (PaCO2). Owing to the
fact that PaCO2 is a strong regulator of cerebral blood
ﬂow, capnography has an important value in intracranial
surgery.1 However, estimation of PaCO2 by monitoring
EtCO2 is not invariably reliable in particular during
hypotension, and capnography monitoring is recom-
mended to be carried out in association with regular
analysis of arterial blood gases during neurosurgery.2
The main factors that modulate the PaCO2 to EtCO2
diﬀerence (PaCO2-EtCO2) are related to alveolar circula-
tion and ventilation during anesthesia.3–6 In the clinical
setting, arterial blood pressure becomes an important
indicator of both systemic and pulmonary perfusion. In
experimental circulatory shock changes, which occur in
cardiac output are reﬂected in the exhaled CO2 concentra-
tion.7 A positive correlation between cardiac output and
EtCO2 has also been shown in patients undergoing vascular
surgery.8,9
The impact of systemic circulation on PaCO2-EtCO2,
however, is far more complex. Russell and Graybeal10
observed a linear correlation between the mean and
diastolic arterial pressures with PaCO2-EtCO2 diﬀerence
in mechanically ventilated neurointensive care patients, but
this was not the case in anesthetized nonneurosurgical
patients.11,12 Furthermore, EtCO2 has been reported to be
greater than PaCO2 in 4% to 13% of patients during
neurosurgery without consistent explanation.13 IncrementCopyright r 2010 by Lippincott Williams & Wilkins
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of fraction of inspired oxygen (FiO2) enlarges PaCO2-
EtCO2.
14 It is also known that coexisting lung disease, the
American Society of Anesthesiologists Physical Status
classiﬁcation, or positioning of the patients modulate
PaCO2-EtCO2.
12,13
In this study, our objective was to determine to
what extent arterial blood pressure changes aﬀects
PaCO2-EtCO2 during the early phase of neuroanesthesia.
The secondary aim was to ﬁnd clinically signiﬁcant
changes in arterial blood pressure that could guide
adjustment toward optimal ventilation, before arterial
blood gas is analyzed.
METHODS
After the study protocol had been approved by the
institutional ethics committee, written informed consent
was obtained from 76 patients who were scheduled to
undergo craniotomy. Those individuals with a history of
pulmonary or cardiac valve decease, decrease state of
consciousness or who already were with an endotraceal
tube or who had had emergency surgery were excluded
from the trial.
On the morning of their operation, the patients were
given their prescribed antiepileptic and antihypertensive
drugs, excluding ACE inhibitors and diuretics. About
1 hour before being taken to the operating theatre, they
received oral diazepam (5 to 15mg). Upon arrival there,
an intravenous drip of acetated Ringer solution was
started into which all drugs would be injected. Non-
invasive blood pressure was then taken with an auto-
mated device, which also measured mean arterial pressure
(MAP). In addition, it monitored heart rate, lead II ECG,
and peripheral oxygen saturation (ADU or Aisys
Integrated Datex-Ohmeda Anesthesia Monitor, Datex-
Ohmeda Inc./GE Healthcare, Madison).
When lying supine, the patients were preoxygenated
(FiO2 1.0, 6 L/min) and then after the administration of
glycopyrrolate and fentanyl, anesthesia was induced with
thiopental. Endotracheal intubation was facilitated by
either suxamethonium or rocuronium. Thereafter, an-
esthesia was maintained with sevoﬂurane or isoﬂurane or
propofol with or without N2O and remifentanil. The
patients were connected to a ventilator receiving a fresh
gas ﬂow of 3L/min (Datex-Ohmeda ADU- or Aisys
General Electric). Positive end-expiratory pressure was
set to zero. FiO2 and other settings would be selected by
the anesthesiologist.
A cannula (20G/1.1 45mm BD Arterial Cannula,
Singapore) was inserted into the radial artery for
sampling of blood gas and for blood pressure measure-
ment and connected to a disposable transducer set (BD
Cabarith PMSET 1DT-XX, Singapore), zeroed at the
level of the foramen of Monro.
Immediately before the patients head was pinned,
an artery sample for analysis of blood gas was taken and
the value of EtCO2 recorded which was to be used for
calculation of PaCO2-EtCO2. Hemodynamic parameters
were registered at 5 minutes intervals after the intubation
and immediately before pinning of the head.
Ventilatory and airway gases were sampled from
the breathing circuit by means of a connection piece ﬁtted
with a ﬁlter (Hygroba ‘‘S,’’ Mallinckrodt Dar, Mirandola,
Italy), which was attached to a ﬂexible tube (DAR
Brathing system, Catheter Mount, Mallinckrodt Dar,
Mirandola, Italy) 20 cm from the upper end of the
tracheal tube. Inspiratory and expiratory tidal volumes
(Vt), minute ventilation (MV), respiration rate, peak and
plateau airway pressures, lung compliance, the ratio of
the duration of inspiration to the duration of expiration,
and airway gas (FiO2, EtCO2, end-tidal O2, end-tidal
sevoﬂurane/isoﬂurane minimum alveolar concentration)
parameters were recorded at the beginning of the
mechanical ventilation, and before the head pinning
without changing patient’s position or ventilator settings
(Datex-Ohmeda AS/3 AM ADU-Aisys General Electric
USA Spirometry). A probe was positioned into the
nasopharynx for measurement of temperature (Mon-
a-therm, Tyco Healthcare, Pleasanton). EtCO2 was mea-
sured using infrared technology in expired gas sampled
through a side-stream spirometry (Side-stream spirometry,
Datex-Ohmeda AS/3 AM. The monitors were calibrated at
regular intervals during the study using a calibration gas
(Quick CAL calibration gas, GE Healthcare Finland Oy,
Helsinki, Finland).
PaO2, PaCO2, and pH, uncorrected for tempera-
ture, were measured with a blood gas analyzer (ABL 825,
Radiometer Medical A/S, Copenhagen, Denmark). Stan-
dard serum bicarbonate concentration and standard base
excess (BE) were analyzed using the classical Henderson-
Hasselbalch equation and the Siggaard-Andersen nomo-
gram.15 The total doses of all drugs given during the study
were also recorded.
Statistical Analysis
The patient characteristics are shown as mean (±SD)
or numbers. Linear regression and analysis of variance
(ANOVA) with LSD test were applied as appropriate.
P<0.05 was considered signiﬁcant. The analysis was done
by StatView PowerPC Version 5.0, SAS Institute Inc.
RESULTS
Seventy-two out of 76 craniotomy patients that
were screened were enrolled in the study. Patient
characteristics and indications for craniotomy are pre-
sented in Table 1.
The mean (SD) time that lapsed between endo-
tracheal intubation and the initial arterial blood gas
sampling was 12.2 (5.6) minutes. A positive correlation
was seen between the percentage change in MAP and
PaCO2-EtCO2 value. The greater the percentage change
in MAP, the greater was the PaCO2-EtCO2 (P=0.0008,
r=0.388) (Fig. 1). There was no correlation between the
time the patient was ventilated and the PaCO2-EtCO2
(P>0.05). None of the PaCO2-EtCO2 was negative. The
mean (SD) minute ventilation and tidal volume were
similar during the time of endotracheal intubation and
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pinning of the head, 87.8 (17.5) mL/kg/min and 7.21
(1.24) mL/kg versus 89.8 (16.3) and 7.25 (1.15), respec-
tively (P>0.05). However, the mean (SD) EtCO2 was
higher after intubation than before pinning of the head,
4.85 (0.53) kPa versus 4.22 (0.43), respectively (P<0.05).
After completion of the study, the patients were
divided into 4 groups according to the diﬀerence in MAP
between MAP awake at arrival in the operating room and
MAP during PaCO2 determination:
1. Group 1 included MAP decrease less than 20% (G-1
group, n=17),
2. Group 2 included MAP decrease of 20-29% (G-2
group, n=24),
3. Group 3 included MAP decrease of 30-35% (G-3
group, n=16) and
4. Group 4 included MAP decrease more than 35% (G-4
group, n=15).
The EtCO2 remained unchanged between the
subgroups (P=0.811) but PaCO2 was found to be
greater in G-4 or G-3 groups than in G-2 or G-1 groups
(P=0.036). Minute ventilation and tidal volume were
similar between the subgroups (P=0.248 and P=0.277,
respectively) (Table 2).
PaCO2-EtCO2 in the subgroups is presented in
Table 2 and Figure 2. The mean PaCO2-EtCO2 was
greater in G-4 group or G-3 group than in G-1 group.
The mean (SD) absolute values of PaCO2-EtCO2 were
0.96 (0.43) kPa or 0.85 (0.31) kPa versus 0.55 (0.24) kPa,
respectively (P<0.05 between the groups).
Side stream spirometry, airway gas parameters, or
arterial partial O2 pressure (PaO2) did not diﬀer between
the subgroups. Neither did a nasopharyngeal temperature
between the subgroups (P>0.05). The mean pH value
ranged within normal laboratory reference range, from
7.41 to 7.45, and was statistically diﬀerent between the
subgroups (P=0.008). All measurements were obtained
when patients temperature were between 35.0 to 36.71C.
There was a signiﬁcant (P=0.01) negative correlation
between FiO2 and PaCO2-EtCO2, whereas no correlation
between PaO2/FiO2 (P/F) ratio change and change in
MAP was found.
MAP in the subgroups is presented in Figure 3. The
MAP before induction was higher in all groups as
compared with MAP values before head pinning
(P<0.05). The MAP was higher in group G-4 than in
G-2 before induction of anesthesia (MAP awake) whereas
the MAP at head pinning was higher in group G-1 than in
G-4 (P<0.05) (Fig. 3). The patients’ heart rate remained in
acceptable clinical limit during the study period.
The doses of drugs used in anesthesia were
comparable between the subgroups (Table 3). The
cumulative doses of propofol or remifentanil until the
time of head pinning did not diﬀer between the subgroups
either (P>0.05). Eight patients received phenylephrine
(mean dose 0.135mg) i.v. during the study period.
Otherwise no vasoactive agents were administered.
According to the neurologic condition we observed
that number of nonruptured aneurysm between the
groups was diﬀerent (Table 1). Other than that, we did
not observe statistically signiﬁcant diﬀerences in patient’s
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FIGURE 1. Correlation analysis comparing (PaCO2-EtCO2)
with (percentage change in mean arterial blood pressures or
MAP) (P=0.0008, r=0.388). Pearson correlation coefficient.
TABLE 1. Patients’ (n = 72) Characteristics and Indications for Surgery and the Subgroup Analysis According to the MAP
Difference
All Patients
n=72
MAP%diﬀ<20
n=17
MAP%diﬀ
20-29 n=24
MAP%diﬀ
30-35 n=16
MAP%diﬀ>35
n=15 P
Age (y) 54.7 (12.5) 54.0 (13.3) 50.5 (14.0) 58.3 (10.4) 58.2 (9.6) 0.157
Weight (kg) 76.2 (14.2) 75.5 (14.0) 76.4 (13.1) 77.4 (14.6) 75.3 (16.8) 0.974
Length (cm) 170.2 (9.6) 170.4 (9.3) 169.8 (8.9) 168.3 (10.7) 172.7 (10.3) 0.657
Smoking (n) 16, 22.2% 4, 23.5% 5, 20.8% 3, 18.8% 4, 26.7% 0.955
Coronary disease (n) 6, 8.3% 2, 11.8% 1, 4.2% 2, 12.5% 1, 6.7% 0.747
Hypertension (n) 29, 40.3% 4, 23.5% 7, 29.2% 9, 56.3% 9, 60.0% 0.062
Diabetes mellitus (n) 5, 6.9% 0, 0% 2, 8.3% 0, 0% 3, 20.0% 0.090
Infratentorial tumor (n) 4, 5.6% 0, 0% 1, 4.2% 2, 12.5% 1, 6.7% 0.459
Supratentorial tumor (n) 34, 47.2% 12, 70.6% 12, 50.0% 4, 25.0% 6, 40.0% 0.063
AVM (n) 2, 2.8% 2, 11.8% 0, 0% 0, 0% 0, 0% 0.084
Nonruptured aneurysm (n) 25, 34.7% 2, 11.8% 7, 29.2% 8, 50.0% 8, 53.3% 0.042
Other operations (n) 7, 9.7% 1, 5.9% 4, 16.7% 2, 12.5% 0, 0% 0.339
Values are mean (SD) or number (n). ANOVA or w2.
AVM indicates arteriovenous malformation.
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characteristics in the subgroup analysis according to the
MAP diﬀerence.
DISCUSSION
A signiﬁcant positive correlation occurred between
the percentage change in MAP and PaCO2-EtCO2 in the
immediate period after anesthesia induction in a hetero-
geneous craniotomy patient population. PaCO2-EtCO2
describes the error in estimating PaCO2 from acute
measurement of EtCO2. The results indicate that the
decrease in MAP plays a signiﬁcant role in PaCO2-EtCO2
during the early phase of anesthesia. PaCO2-EtCO2 was
greater in patients with a MAP decrease over 30% than
in patients with a MAP decrease less than 20%. This
suggests that more than 30% decrease in MAP is
clinically important and should be taken into account
when optimal ventilation is adjusted before arterial blood
gas sampling.
Our ﬁndings are in accordance with earlier studies
in neurosurgical patients.2,10,13 Monitoring of EtCO2 as
an estimate of PaCO2 is misleading, and, thus, optimal
ventilation in the start of anesthesia must be conﬁrmed by
arterial blood gas analysis. However, the settings of the
ventilator have to be adjusted according to the EtCO2
in the early phase of mechanical ventilation. At this stage,
anesthesiologist has to take into account the patient’s
intracranial pathology, method of anesthesia, estimation
of systemic and pulmonary circulation, and alveolar
ventilation.
The patients’ minute ventilation did not diﬀer
between the subgroups. Nevertheless, slightly lower
minute ventilation values were measured in G-3 and
G-4 than in G-2 and G-1 group. This may suggest that the
mechanical ventilation was adjusted by the anesthesiolo-
gist exclusively according to the EtCO2 value. In fact, the
TABLE 2. Respiratory Parameters and Subgroup Analysis According to the MAP Difference
MAP%diﬀ
<20 n=17
MAP%diﬀ
20-29 n=24
MAP%diﬀ
30-35 n=16
MAP%diﬀ
>35 n=15 P
MV/kg (ml/kg/min) 92.0 (11.1) 94.0 (16.7) 85.1 (18.9) 85.7 (17.0) 0.248
TVet/kg (ml/kg) 7.61 (1.04) 7.36 (1.18) 6.93 (1.31) 7.00 (0.97) 0.277
RR (times/min) 11.9 (1.3) 12.3 (1.0) 11.8 (1.3) 11.7 (1.3) 0.481
FiO2 (0-1.0) 0.50 (0.06) 0.49 (0.06) 0.48 (0.06) 0.48 (0.05) 0.821
EtO2 (0-1.0) 0.47 (0.06) 0.46 (0.06) 0.45 (0.06) 0.44 (0.05) 0.547
PaO2 (kPa) 27.1 (7.1) 25.5 (9.2) 22.5 (7.5) 25.1 (8.7) 0.454
EtCO2 (kPa) 4.21 (0.49) 4.17 (0.39) 4.22 (0.49) 4.31 (0.39) 0.811
PaCO2 (kPa) 4.76 (0.60) 4.84 (0.51) 5.07 (0.59) 5.25 (0.37) 0.036
PaCO2-EtCO2 (kPa) 0.55 (0.24) 0.67 (0.41) 0.85 (0.31) 0.96 (0.43) 0.009
Compliance (mL/cmH2O) n=15
56.5 (11.8)
n=21
62.7 (14.5)
n=14
58.1 (13.4)
n=15
56.7 (22.7)
0.616
Peak airway pressure (cmH2O) 17.7 (3.5) 17.5 (3.7) 16.0 (2.0) 17.3 (4.4) 0.508
Plateau airway pressure (cmH2O) 12.6 (4.2) 12.0 (3.1) 12.4 (1.4) 13.1 (3.9) 0.784
pH (normal 7.35-7.45) 7.45 (0.04) 7.43 (0.03) 7.43 (0.03) 7.41 (0.02) 0.008
BE (normal  2.5-+2.5) 0.94 (1.37) 0.10 (1.84) 1.00 (1.51) 0.39 (1.71) 0.263
Values are mean (SD) or number (n). ANOVA or w2.
MV indicates minute ventilation; RR, respiratory ratio; TV, tidal volume.
* p<0.01 vs MAP%diff <20
* * p<0.05 vs MAP%diff <20
# p<0.01 vs MAP%diff 20-29
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FIGURE 2. Mean (SD) PaCO2-EtCO2 between mean arterial
blood pressures MAP%diff groups.
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patients were similarly ventilated according to the EtCO2
in the study groups, even though PaCO2 was increased in
patients with pronounced decrease in MAP.
The contribution of MAP on PaCO2-EtCO2 under
conditions of this study is furthermore supported by the
fact that pulmonary artery pressure is inversely related to
the EtCO2 to PaCO2 diﬀerence in anesthetized patients.
15
Furthermore, our observation is of clinical importance as
cerebral CO2-reactivity is impaired during hypotension.
1
Therefore, hypercapnia-induced cerebral vasodilatation,
or hypocapnia-induced cerebral vasoconstriction may be
severely impaired if the patient becomes hypotensive.1 In
clinical practice this indicates that the cerebral blood ﬂow,
and thus, the intracranial pressure, cannot be aﬀected
by modifying the PaCO2 tension in hypotensive patients.
Potential hypoventilation may be avoided in neurosurgi-
cal patients with marked decrease of MAP by increasing
minute ventilation more than indicated by EtCO2.
Earlier studies indicate that inhalation anesthetics
may reduce hypoxic pulmonary vasoconstriction and
increase shunt dead space.16–18 However, there are also
studies contradicting this.19,20 Therefore, the clinical
relevance of the eﬀect of inhalation anesthetics have on
hypoxic pulmonary vasoconstriction remains controver-
sial. In contrast to inhalation anesthetics, propofol has
been shown to have a neutral eﬀect on hypoxic
pulmonary vasoconstriction or may even potentiate
it21,22 particularly if compared with the eﬀect of volatile
anesthetics.23 In this study, the method of anesthesia was
not standardized. It was chosen according to the patient’s
clinical condition together with CT or MRI ﬁndings. For
example, if the patient had elevated intracranial pressure
or history of postoperative nausea and vomiting, volatile
anesthetics were not used. However, the type of anesthe-
sia used was comparable between the subgroups.
This study has some limitations. The baseline blood
pressure was measured noninvasively followed by inva-
sive arterial pressure measurements at level of foramen
Monroe. As these 2 diﬀerent ways of measuring MAP
were not done at the same time, we lack the data
concerning their comparability. However, this procedure
reﬂects the standard practice in our clinic. Noninvasive
blood pressure before anesthesia induction is an important
indicator of the patient’s circulation and essential in the
process of optimization of hemodynamics later during
anesthesia. Our observation of the change of MAP may
also be slightly exaggerated as in supine position, head
slightly elevated, the diﬀerence between systolic blood
pressure at brain and heart level is approximately 5 to
10mm Hg. Furthermore, in our study, the patients were
preoxygenated with 100% oxygen during induction of
anesthesia before intubation and thereafter FiO2 (mean
approximately 0.5) was decided by the anesthesiologist. It is
known that the increment of FiO2 will increase PaCO2-
EtCO2.
14 This eﬀect, however, is minimal. Ito et al14
reported that the change at its maximum was only 0.2 kPa
when FiO2 was increased from 0.21 to 0.97. Moreover, in
our study there was signiﬁcant (P=0.01) negative correla-
tion between FiO2 and PaCO2-EtCO2. Rusca et al
24 state
that 100% oxygen leads to lung atelectasis and, conse-
quently an increase in intrapulmonary shunt. They did not,
however, report what eﬀect atelectasis formation had on
PaCO2-EtCO2. Our observation of no correlation between
P/F ratio change and MAP decrease may indicate that
MAP aﬀects CO2 diﬀerence independently of atelectasis.
Cardiac output, pulmonary artery pressure, and
pulmonary shunting were not measured in this study.
Therefore, the physiologic explanations of our ﬁndings
remain speculative. However, the results do shed light on
the controversial view of the eﬀect of MAP on PaCO2 to
EtCO2 diﬀerence during early period of neuroanesthesia.
The conﬂicting results of earlier PaCO2-EtCO2 studies
may have been biased by the limited cardiovascular
monitoring or unreported alterations in hemody-
namics.2,10,13 Furthermore, in contrast to earlier studies,
we did not ﬁnd greater EtCO2 than PaCO2 values,
indicating that proper ventilator settings were used, which
gives reliability in our ﬁndings. Nevertheless, the relation-
ships between hemodynamical alterations and PaCO2 to
EtCO2 diﬀerence need future research.
In summary, the eﬀect of a possible decrease in
arterial blood pressure should be taken into consideration
TABLE 3. Anesthetics Used and Patients’ Temperature in the Subgroup Analysis According to the MAP Difference
MAP%diﬀ
<20 n=17
MAP%diﬀ
20-29 n=24
MAP%diﬀ
30-35 n=16
MAP%diﬀ
>35 n=15 P
Temperature (1C) n=17
36.2 (0.4)
n=22
36.2 (0.3)
n=16
36.1 (0.3)
n=15
36.0 (0.5)
0.315
Propofol (mg/kg) 1.06 (0.80) 0.75 (0.83) 0.48 (0.54) 0.71 (0.82) 0.205
Remifentanyl (mg/kg) 3.18 (4.24) 3.24 (5.78) 3.06 (6.74) 2.73 (4.22) 0.993
Tiopental (mg/kg) 4.76 (1.20) 5.21 (1.39) 4.37 (1.10) 5.14 (1.84) 0.264
Fentanyl (mg/kg) 4.68 (2.11) 5.28 (1.52) 5.58 (1.51) 5.47 (1.53) 0.428
Rocuronium (mg/kg) n=16
0.70 (0.11)
n=21
0.66 (0.13)
n=16
0.67 (0.15)
n=15
0.71 (0.12)
0.649
Anesthesia (n)
Propofol 11 11 7 7
Propofol+N2O 4 5 4 3
Isoﬂurane or Sevoﬂurane 2 8 5 5 0.787
Values are mean (SD) or number (n). ANOVA or w2.
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when mechanical ventilation is optimized before obtain-
ing results of arterial blood gas analysis in the early phase
of neuroanesthesia. In this way, potential hypoventilation
may be avoided in neurosurgical patients with marked
(>30%) decrease of MAP.
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Abstract 
 
Background 
 
General anesthesia exposes patient to hemodynamic alternations both in prone and sitting 
position. As the comparison of the sitting and prone position in neurosurgery is scarce, we 
aimed to evaluate hemodynamic profile during stroke volume-directed fluid administration 
in patients undergoing neurosurgery either in sitting or prone position.  
 
Methods 
 
Thirty patients in prone and 28 in sitting position in two separate prospective trials were 
randomized to receive either Ringer’s Acetat (RAC) or hydroxyethyl starch (HES 130 
kDa/0.4) for optimization of stroke volume. After combining data from these two trials the 
two-way analysis of variance was performed to compare patient hemodynamic profile 
between the two positions and to evaluate differences between RAC and HES 
consumption. 
 
Results 
 
To achieve comparable hemodynamics during surgery higher mean cumulative dose of 
RAC than HES was needed (678±390 ml vs 455±253 ml, respectively, p < 0.05) However, 
when fluid consumption was adjusted with weight, statistical difference was lost. Fluid 
administration was similar weather patient was in prone or sitting position. Mean arterial 
pressure was lower and cardiac index and stroke volume index was higher overtime when 
patient was in sitting position. 
 
Conclusion 
 
Sitting position does not require excess fluid treatment compared to prone position. HES is 
slightly more effective than RAC in achieving comparable hemodynamics, but difference 
might be explained by patient weight. With goal directed fluid administration and moderate 
use of vasoactive drugs it is possible to achieve stable hemodynamics in both position. 
 
Introduction 
 
Neurosurgery in general anesthesia exposes patient to hemodynamic alternations, i.e 
hypotension and changes in cardiac function, both in prone and sitting position 1-4.  
Regarding intraoperative fluid administration, it was earlier thought that colloids are 
superior to crystalloids in increasing hypovolemic patients’ intravascular but recent findings 
show that difference might notably smaller than was earlier believed 5,6. Similarly, a slightly 
better capability to improve cardiac stroke volume has been reported with colloids 5. 
Recent controversies regarding colloids safety, however, have diminished their use 7,8.  
Some neurosurgical procedures can be performed either in sitting or prone position, but 
comparison of these two positions is scarce 9.  
 
The aim of the current study was to use the prospectively collected data on hemodynamics 
and fluid volumes in the sitting and prone position and to find out the possible differences 
between sitting and prone position in patient’s hemodynamic profile and stroke volume-
directed fluid administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
 
This study consists of two separate patient enrolments. In the first part, adult patients 
scheduled for elective primary neurosurgery in the prone position at the neurosurgical 
department of Helsinki University Central Hospital were included in the study. The second 
phase comprised patients scheduled for elective craniotomy in the sitting position at the 
same institute. The Ethics Committee for Surgery of the Hospital District of Helsinki and 
Uusimaa approved both trials (Ethics Committee Numbers 13/13/03/04/09 HUS and 
396/E9/2007). Additionally, the National Agency of Medicines in Finland accepted the 
study protocols (EudraCT Ref. No 2009-009893-28 and EudraCT ref. no. 2007–007106-
30). All patients gave their written, informed consent to partake in the study. 
 
Patients younger than 18 years old, with body mass index (BMI) > 36 kg/m2 in the prone 
position or > 40 kg/m2 in the sitting position, congestive heart failure, other than sinus 
rhythm in electrocardiography (ECG), renal failure (plasma creatinine > 120 ?mol/l), 
hepatic failure, anemia (hemoglobin < 100 g/l), and thrombocytopenia (platelet count < 
100x109/l) were excluded. Additionally, expected use of mannitol in sitting position resulted 
in exclusion.  
 
Patients received their antihypertensive mediations excluding the angiotensin-converting 
enzyme inhibitors preoperatively. Additionally, oral diazepam 5-20 mg served as a 
premedication.  
 
Before the anesthesia induction a basal Ringer’s acetate (RAC) infusion was commenced 
at the rate of 3 ml/kg/h (an additional 40 mmol/l of NaCl were added to RAC basal infusion 
of patients in a sitting position). All patients received preoperative antibiotics (cefuroxime 
or vancomycin). 
 
Anesthesia was induced in the supine position with fentanyl 2–7 ?g/kg and either 
thiopental 2–7 mg/kg or propofol 2–3 mg/kg. All patients received glycopyrrolate 0.2 mg. 
Rocuronium (0.5–0.9 mg/kg) was used for muscle relaxation. Anesthesia was maintained 
with sevoflurane (1 MAC) in a mixture of nitrous oxygen and air and additional fentanyl 
boluses or a continuous infusion of propofol (4–10 mg/kg/h) and remifentanil (0.125–0.25 
?g/kg/h) with patients operated on in prone position and with a continuous infusion of 
propofol (4–12 mg/kg/h) and remifentanil (0.05–0.45 ?g/kg/h) with patients in sitting 
position with the permission the use sevoflurane to treat severe hypertension. 
 
After tracheal intubation, a volume controlled mechanical ventilation without positive end-
expiratory pressure (PEEP) was started (tidal volume 8-10 ml/kg body weight and rate of 
10-15/min) targeting to a normoventilation (PaCO2 4.5-5.0 kPa). 
 
Anesthesia monitoring prior intubation included noninvasive arterial blood pressure, ECG 
(lead II) and arterial saturation of oxygen (SpO2). After tracheal intubation, monitors of 
nasopharyngeal temperature, side-stream spirometry (Side stream®, Datex-Ohmeda Inc, 
GE Healthcare, Madison, WI, USA) and end-tidal concentration of carbon dioxide were 
applied. Additionally, a 20G arterial catheter (Becton Dickinson, Temse, Belgium) was 
inserted into the radial artery for invasive monitoring of arterial pressures and to obtain 
blood samples. 
 
To continuously monitor cardiac output (CO), cardiac index (CI), stroke volume (SV), 
stroke volume index (SVI), and stroke volume variation (SVV), the Vigileo System 
(Edwards Lifesciences) with software version 3.02 was applied by connecting it to arterial 
line with a pressure transducer set (FloTrac; Edwards Lifesciences, Irvine, CA, USA) 
zeroed at the heart level. For patients operated on in sitting position an additional set was 
applied and zeroed at the level of foramen Monroi for the measurement of systolic, 
diastolic, and mean arterial pressure (MAP). 
 
Both study sequences (prone and sitting position) had the same protocol for the study fluid 
administration. Patients were randomly assigned (using closed envelopes drawn in 
sequential order by the primary investigators) in blocks of three to receive one of the 
following study solutions: 
 
1. 6% HES solution (Voluven®; 60 mg/ml, average molecular weight 130 kDa, molar 
substitution ratio 0.4, pH 4.0–5.5, contents Na+ 154 mmol/l, Cl- 154 mmol/l; Fresenius 
Kabi, Bad Homburg, Germany) (HES group, n = 15 in prone position + 15 in sitting 
position); and 
2. Ringer’s acetate solution (Ringer-acetate®, pH 6.0, contents Na+ 130 mmol/l, Cl- 112 
mmol/l, 
K+ 4 mmol/l, Ca++ 2 mmol/l, Mg++ 1 mmol/l, CH3COO- 30 mmol/l; Fresenius Kabi) (RAC 
group, 
n = 15 in prone position + 13 in sitting position). 
 
After anesthesia induction, while lying supine, all patients received an initial 200 ml bolus 
of the study fluid over 2–4 min, and hemodynamic measurements were performed before 
and 3 min after the administration of study fluid. A new bolus of 100 ml over 2–4 min was 
given immediately after the hemodynamic measurements, until SV did not increase more 
than 10 %. The hemodynamic measurements were performed 3 minutes after each bolus.  
 
Thereafter, patients were positioned for surgery. Patients in sitting position were dressed 
in an antigravity suit prior positioning. Registration of hemodynamic parameters took place 
at 5 min intervals during surgery. If SV decreased more than 10% from the value obtained 
in the supine position, further study fluid boluses of 100 ml were administered. If the SV 
did not increase with three consecutive boluses, the volume expansion was stopped and 
the patient was considered as non-responder. Hemodynamic parameters were registered 
also at the end surgery and after patient positioning back to supine position. 
 
The target for MAP was 60 mmHg or higher at the brain level. Boluses of phenylephrine 
(0.05–0.1 mg) or ephedrine (5–10 mg) were given if MAP was below 60 mmHg despite the 
study fluid administration. A phenylephrine or norepinephrine infusion was started 
whenever MAP remained below 60 mmHg for more than 5 min. 
 
Basal infusion of RAC (with 0,9% NaCl supplement if required) continued at the rate of 
1ml/kg/h until the first postoperative morning. Registration of urine output and fluid balance 
took place at pre-determined intervals. 
 
Patient positioning  
 
In prone position bilateral chest supports were used and patient’s head was placed on a 
headrest (Prone View Protective Helmet System; Dupaco, Oceanside, CA, USA), or fixed 
with the Sugita pin head-holder device (Sugita Head Frames; Mizuho America, Union City, 
CA, USA). 
 
In sitting position the patient’s upper body was elevated 50–100 degrees, head attached to 
a head holder device (Mayfield; Integra Life Sciences, Plainsboro, NJ, USA) and tilted 20–
30 degrees forward with the patient sitting with knees slightly flexed on a pillow. For the 
detection of possible venous air embolism, the probe of pre-cordial Doppler (Versatone D8 
Perioperative Doppler; Med-Sonics Inc, Mountain View, CA, USA) was placed over the 
right fifth intercostal space lateral to sternum. 
 
This study consists of two previously executed trials; stroke volume-directed administration 
of study fluids with patients operated on in prone position and, another trial in which 
different group of patients were operated on in sitting position. Results of differences 
between the study fluids in achieving stable hemodynamics within one surgery position 
and also the effect these two fluids have on patient blood coagulation measured by 
Rotem® analysis have been reported earlier in two separate publications 10,11. 
 
 
Statistics 
 
 
We performed this analysis post hoc by combining the data of the study fluid usage, 
patient's hemodynamics and basic patient demography from the two previously executed 
trials. 
 
Two-way variance of analysis (ANOVA) was used to test differences between the study 
groups (prone vs sitting position; HES vs RAC). When needed, T-test was used to 
determine differences between two groups. Results are shown as mean and standard 
deviation (SD). P< 0.05 was considered statistically significant. 
 
Hemodynamic data is shown graphically as means at time points from 0 to 230 at 5-minute 
intervals. If needed, the difference between curves could have been tested using Sign 
Test. In all cases the P-value would be P<0,000001 or less. 
 
Results 
 
Data from 58 patients (30 patients in prone and 28 in sitting position) were analyzed after 
assessment of 72 patients for eligibility between August 2009 and March 2011. Exclusion 
flowcharts have been reported in conjunction with the original reports of both individual 
studies 10,11 
 
The combined data shows, when divided in two groups according to the study fluid (RAC 
vs HES) that patients in RAC group had higher weight, height and higher body surface 
area (BSA). However, the body mass index (BMI) was equal in both groups (table 1). 
Cumulative mean dose of basal RAC was similar between the study groups. When divided 
according to the surgery position, the groups were comparable with the exception that 
patients in the sitting position were younger (p < 0.01) and had higher ASA classification 
(p<0.001) (table 2).  
 
The mean cumulative doses of RAC (prone and sitting position combined) to optimize the 
fluid filling at 30 min and end of surgery was higher than dose of HES (452±155 ml vs 
341±109 ml and 678±390 ml vs 455±253 ml, respectively) (table 3). When RAC and HES 
doses were adjusted with patient’s weight the mean doses at 30 min and at the end of 
surgery for RAC still remained higher than those of HES (5.5±1.6 ml/kg vs 4.8±1.7 and 
8.2±4.2 ml/kg vs 6.4±3.6 ml/kg, respectively), but statistical significance was lost. RAC and 
HES doses before positioning were similar in both positions. 
 
Patients in sitting position had lower MAP overtime and higher CI and SVI than patients in 
prone position (Figure 1). Regarding the patients position during surgery, there was now 
difference in study fluid consumption between the two groups (table 3). 
 
 
 
 
 
 
 
 
Discussion 
 
This study shows that sitting position in neurosurgery does not require excess intravenous 
fluid administration in comparison with surgery done in prone position. Moreover, the 
benefit of using HES solutions to optimize patient hemodynamics instead of RAC is only 
marginal. With goal directed fluid administration and moderate use of vasoactive drugs it is 
possible to achieve stable hemodynamics in both position. 
 
Neurosurgery in sitting position was more popular in 70’s and 80’s as it is today. Even 
today, there is a great variation in its occurrence between the countries where sitting 
position is used 12. Sitting position is still often considered preferable when operating on 
lesions in posterior cranial fossa 9,13. Advantages of sitting position is decreased 
intracranial pressure, and a clearer operating field due to gravity forced downward 
drainage of blood and cerebrospinal fluid. Surgery in a sitting position also decreases the 
incidence of cranial nerve damage 13. Sitting position is known to cause hypotension and 
decrease in cardiac function, setting a challenge to neuroanesthesia in guaranteeing 
sufficient cerebral blood pressure and oxygen delivery. Another concern of sitting position 
is venous air embolism (VAE), which has an incidence of 1.6-50%, number being lower in 
semisitting position 1,3,10,14-17 
 
Historically, it was believed that colloids capability to increase intravascular volume in 
hypovolemic patients would be 2-3 fold compared to crystalloids, but recent findings 
indicates that 1:1 to 1:1.5-1.8 is the more accurate ratio 5,6,18. Similar ratio was found in 
elective neurosurgery patients 10,11. Our result showed a ratio of 1:1.5 between HES and 
RAC in achieving comparable hemodynamics, which is in line with the earlier findings. 
Interestingly, even this might be an overestimation, because when adjusted with patients’ 
weight, difference in HES and RAC doses can be seen (1:1.3), but it is not statistically 
significant anymore.  
 
In this current study, we demonstrated that the previously reported decrease in cardiac 
function, when prone position is applied, can be prevented with stroke volume-directed 
fluid administration and moderate use of vasoactive drugs 19-22. Moreover, with similar fluid 
and vasoactive drug administration, patients in sitting position maintained good cardiac 
function after positioning and decrease in cardiac function did not occur 1. Although MAP 
remained adequate throughout the surgery, it was lower in sitting position, confirming 
tendency of hypotension in this position. Patients in the sitting position in our study were 
antigravity suits, which in part prevents pooling of the blood in the lower extremities and, 
thus, help stabilizing patient hemodynamics. Patients in sitting position had higher CI than 
patients operated on supine. That possible reflects to patients in sitting position being 
healthier and younger. Noteworthy is that anesthesia was maintained with propofol in 
sitting position while mainly volatile anesthetics were used in supine position. This adds to 
the complexity of CI interpretation 23.  
 
As there is great variety in methods of measuring cerebral perfusion pressure (CPP) in 
neurosurgical patients, it should be noted that we measured the MAP at the level of 
foramen Monroi giving us more accurate estimate of cerebral perfusion pressure (CPP). If 
MAP would have been measured at the level of heart, would the values be 15-25 mmHg 
higher and reflecting more to the systemic blood pressure 24,25.  
 
Discussion about safety of artificial colloids is ongoing. Increased risk of mortality and 
kidney failure in critically ill patients is associated with the use of hydroxyethyl starch and 
related consensus statement have decreased use of artificial colloids dramatically 7,8,26 . 
Recent years have seen plethora of reports trying to determine whether these risk are 
factual in other patient population as well (i.e. general surgery patients). Possible negative 
effect colloids have on coagulation is important to bear in mind when treating 
neurosurgical patients as normal coagulation capacity in this patient population is essential 
27. Although the initial filling dose of study fluids where not enough to stabilize 
hemodynamics before positioning, the total doses of intraoperative fluids in our study were 
low and only minor difference in doses was seen between HES and RAC. In that light, it 
would be difficult to recommend HES use also with patients operated on in sitting position 
in this patient population.  
 
We conclude, that neurosurgery in sitting position does not require excessive fluid 
administration compared to prone position in achieving stable hemodynamics. Possible 
minor benefit gained from using HES to diminish fluid load is counteracted by the possible 
harms associated with the use of artificial colloids.  
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Table 1 
 
Patients characteristics when diveded according to the study fluid (HES or RAC). 
 
 HES RAC p 
M/F 6/23 15/14 < 0.05 
Age (years) 48±16 48±19 ns 
Weight (cm) 73.3±12.9 82.0±15.4 < 0.05 
Height (kg) 165.8±8.8 171.6±9.3 < 0.05 
BSA (m2) 1.83±0.18 1.97±0.23 < 0.05 
ASA I/II/III/IV 2/8/18/1 4/5/18/2 ns 
Basal RAC 
(ml) 
783±218 819±309 ns 
 
Data are presented mean ± standard deviation, ns=non significant. 
ASA, American Society of Anesthesiologists; BSA, body surface 
area; HES, hydroxyethylstarch 130/0.4; RAC, Ringer’s acetate 
 
 
Table 2 
 
Patients characteristics when diveded according to the surgery position (prone or sitting). 
 
 Prone Sitting p 
M/F 13/17 8/20 ns 
Age (years) 54±18 42±15 < 0.01 
Weight (cm) 79±15 76±14 ns 
Height (kg) 170±8 167±9 ns 
BSA (m2) 1.93±0.22 1.88±0,20 ns 
ASA I/II/III/IV 6/13/10/1 0/0/26/2 <0.001 
Efedrin total dose (mg) 9.2±4.9 4.4±1.3 ns 
Neosynphrine tot dose 
(mg) 
1.4±1.7 1.4±2.3 ns 
 
Data are presented mean ± standard deviation, ns=non significant 
ASA, American Society of Anesthesiologists; BSA, body surface 
area;  
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
 
Study fluid (RAC and HES) consumption in two different surgery position and positions 
combined (prone and sitting). 
 
Fluid Sitting Prone Position 
Combined 
P value 
HES total ml 464±284 447±229 455±253  
RAC total ml 707±425 653±368 679±390  
Study fluids 
combined 
586±376 550±319 567±345 < 0.05 (between the 
fluids) 
     
HES start bolus 
ml 
271±47 240±51 255±51  
RAC start bolus 
ml 
264±50 267±62 266±55  
Study fluids 
combined 
268±48 253±57 260±53 ns 
     
HES at 30 min ml 343±94 340±124 341±109  
RAC at  30 min ml 450±156 453±160 452±155  
Study fluids 
combined 
396±137 397±152 397±144 < 0.001 (between the 
fluids) 
 
 
Data are presented mean ± standard deviation, ns=non significant. 
HES, hydroxyethylstarch 130/0.4; RAC, Ringer’s acetate 
?
 
 
 
Figure 1 
Mean arterial pressure (MAP), cardiac index (CI) and stroke volume index (SVI) over time 
(minutes) during surgery in sitting and prone position. 
 
 
  
 
 
Studies on Hemodynamics and Coagulation in 
Neuroanesthesia
DIVISION OF ANESTHESIOLOGY
DEPARTMENT OF ANESTHESIOLOGY
INTENSIVE CARE AND PAIN MEDICINE
FACULTY OF MEDICINE
DOCTORAL PROGRAMME IN CLINICAL RESEARCH
UNIVERSITY OF HELSINKI AND
HELSINKI UNIVERSITY HOSPITAL
TEEMU LUOSTARINEN
DISSERTATIONES SCHOLAE DOCTORALIS AD SANITATEM INVESTIGANDAM
UNIVERSITATIS HELSINKIENSIS 81/2015
81/2015
Helsinki 2015 ISSN 2342-3161          ISBN 978-951-51-1557-7
T
E
E
M
U
 L
U
O
S
T
A
R
IN
E
N
    S
tu
d
ies on
 H
em
od
yn
am
ics an
d
 C
oagu
lation
 in
 N
eu
roan
esth
esia
Recent Publications in this Series
61/2015 Jussi Kupari
Studies on Peripheral Nervous System Development and Function in Mice Defi cient for the 
Neurturin Receptor GFRα2
62/2015 Anton Tokariev
Studying Connectivity in the Neonatal EEG
63/2015 Eva María del Amo Páez
Computational Prediction and Pharmacokinetic Simulations for Drug Discovery and 
Development
64/2015 Reija Silvennoinen
Physiological Modulation of the Reverse Cholesterol Transport Pathway in vivo
65/2015 Heli Venhoranta
Inherited Developmental Diseases Related to Reproductive Failures in Cattle
66/2015 Juhana Rautiola
Angiogenesis Inhibitors in Metastatic Renal Cancer with Emphasis on Prognostic Clinical and 
Molecular Factors
67/2015 Terhi Peuralinna
Genetics of Neurodegeneration: Alzheimer, Lewy Body and Motor Neuron Diseases in the 
Finnish Population
68/2015 Manuela Tumiati
Rad51c is a Tumor Suppressor in Mammary and Sebaceous Glands
69/2015 Mikko Helenius
Role of Purinergic Signaling in Pathological Pulmonary Vascular Remodeling
70/2015 Kaisa Rajakylä
The Nuclear Import Mechanism of SRF Co-Activator MKL1
71/2015 Johanna Lotsari-Salomaa
Epigenetic Characteristics of Lynch Syndrome-Associated and Sporadic Tumorigenesis
72/2015 Tea Pemovska
Individualized Chemical Systems Medicine of Acute and Chronic Myeloid Leukemia
73/2015 Simona Bramante
Oncolytic Adenovirus Coding for GM-CSF in Treatment of Cancer
74/2015 Alhadi Almangush
Histopathological Predictors of Early Stage Oral Tongue Cancer
75/2015 Otto Manninen
Imaging Studies in the Mouse Model of Progressive Myoclonus Epilepsy 
of Unverricht-Lundborg Type, EPM1
76/2015 Mordekhay Medvedovsky
Methodological and Clinical Aspects of Ictal and Interictal MEG
77/2015 Marika Melamies
Studies on Canine Lower Respiratory Tract with Special Reference to Inhaled Corticosteroids
78/2015 Elina Välimäki
Activation of Infl ammasome and Protein Secretion by Endogenous Danger 
and Microbe-Derived Signals in Human Macrophages
79/2015 Terhi Keltanen
Postmortem Biochemistry - Analysis of Metabolic Imbalance
80/2015 Mari Savolainen
The Effects of Prolyl Oligopeptidase Inhibition in α-Synuclein Based 
Mouse Models of Parkinson’s Disease
